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Abstract: Die autosomal dominante polyzystische Nierenerkrankung (ADPKD) ist die häufigste monogen
vererbbare Nierenerkrankung und etwa 50% der betroffenen Patienten werden zwischen dem 50. und 60.
Lebensjahr nierenersatzpflichtig. Ein zentrales Therapieziel ist die Verlangsamung der Krankheitspro-
gression, wofür einerseits die Krankheitsprogression prognostiziert werden und anderseits entsprechende
Massnahmen für das ADPKD Management getroffen werden müssen. Im Jahr 2016 wurde das erste
Medikament Tolvaptan zur Verlangsamung der Krankheitsprogression für einen schweren Verlauf zuge-
lassen (Schweiz). Bis dahin konnten nur Begleiterkrankungen behandelt werden und daher waren Anpas-
sungen des Lebensstils umso wichtiger für das ADPKD Management. Diese Dissertation beinhaltet drei
Studien, welche zu einem evidenzbasierten ADPKD-Management beitragen. In der ersten Studie wurde
der kausale Zusammenhang zwischen Kaffeekonsum und der Krankheitsprogression in der Schweizer
ADPKD Kohorte untersucht. Die unaufhaltsame Progression von ADPKD hat viele Ärzte dazu ver-
anlasst, eine Reduzierung von Risikofaktoren wie dem Kaffeekonsum zu empfehlen, dies trotz fehlender
klinisch- epidemiologischer Studien. Die Ergebnisse unserer Studie, welche die erste longitudinale Studie
überhaupt ist, zeigten eine bessere Nierenfunktion und einen leicht milderen Abfall der Nierenfunktion bei
ADPKD Patienten mit Kaffeekonsum im Vergleich zu ADPKD Patienten ohne Kaffeekonsum. Demnach
bestätigen unsere Ergebnisse die in vitro Ergebnisse nicht, dass Kaffee ein Risikofaktor für einen schweren
ADPKD Verlauf ist. In der zweiten Studie war es das Ziel, einen Triage Test zu entwickeln, der Patienten
identifiziert, die noch unterhalb des Nierenvolumens liegen, welches zur Verschreibung des Medikaments
Tolvaptan notwendig ist und damit unnötige MRTs vermieden werden können. Diese Studie adressiert
die Herausforderung im ADPKD Management, dass derzeit bei allen Patienten eine Messung des to-
talen Nierenvolumens (TKV) mit Magnetresonanzbildgebung (MRT) durchgeführt werden müsste, um
die Indikation für eine Therapie mit Tolvaptan zu bestimmen. MRT- Untersuchungen sind jedoch teuer,
erfordern spezifische Expertise bei der Analyse und sind daher nicht immer verfügbar. Daher entwickelten
wir einen in der Anwendung einfachen Test basierend auf demographischen Angaben der Patienten und
Labordaten von 204 Patienten der Schweizer ADPKD Kohorte mittels Regressionsmodellen und einer
anschließenden Bewertung des diagnostischen Tests. Ein sequentielles Triage Testverfahren erreichte eine
Sensitivität von über 90%. Der Triage-Test kann zu einer besseren Allokation der Ressourcen führen, da
Patienten, die (noch) nicht für eine Therapie mit Tolvaptan qualifizieren, mit einfach zugänglicher Infor-
mation zuverlässig identifiziert werden müssen, für die keine MRT- Untersuchung nötig ist. In der dritten
Studie führten wir schliesslich die erste Validierungsstudie eines prominenten Vorhersagemodells für den
Verlauf der ADPKD durch, welche von Wissenschaftler der Mayo Klinik entwickelt wurde. Ein Vorher-
sagemodell ist im klinischen Umfeld nützlich zur Identifikation von Patienten mit einem erhöhten Risiko
für einen schweren Verlauf, bei denen eine aggressivere Behandlung trotz Nebenwirkungen indiziert sein
kann. In unserer zeitlich - und räumlich externen Validierung der zwei Mayo Klinik Modelle zeigte sich,
dass die Modelle auf eine wesentlich andere Population (Schweizer ADPKD Kohorte) generalisierbar sind
und diese eine valide Methode darstellen, um Patienten mit einem zu erwartendem schweren Verlauf zu
identifizieren. Ein erweitertes Modell mit zusätzlichen Informationen zum Nierenvolumen verbesserte die
Vorhersagekraft des Modells nicht wesentlich. Die drei Studien dieser Dissertation tragen dazu bei, das
zentrale Therapieziel der Verlangsamung der Krankheitsprogression zu verfolgen. Die hier entwickelten
und untersuchten Triage-Tests und Vorhersagemodelle unterstützen evidenzbasierte Entscheide von Pa-
tienten und Ärzten zum Einsatz von aufwändigen diagnostischen Tests und zur Indikationsstellung von
nichtmedikamentösen und medikamentösen ADPKD-Therapien. Autosomal dominant polycystic kidney
disease (ADPKD) is the most common monogenic inherited renal cystic kidney disease and approximately
50 % of the patient’s progress to end stage renal disease between the 5th and 6th decade of their life. A
major therapy goal is to slow down disease progression. To achieve this, it is necessary to predict disease
progression and to implement ADPKD management that balances the benefits, harms and cost appropri-
ately. In 2016, tolvaptan was approved as the first drug to slow down disease progression in ADPKD and
it is indicated for patients with rapid disease progression in Switzerland. Before the availability of tolvap-
tan, treatment focused on managing co-morbidities through medication and life style modification. This
PhD thesis includes three studies, which contribute to an evidence-based management in ADPKD. The
first study assessed the association between coffee consumption and disease progression in a longitudinal
ADPKD cohort. The relentless progression of ADPKD means that most ADPKD experts are inclined
to advocate the minimisation of risk factors for rapid disease progression such as caffeine consumption,
despite the absence of clinical-epidemiological data indicating benefit. Our study results, which were, to
our knowledge, based on the first longitudinal study that ensures temporality to assess the relationship
between coffee consumption and disease progression, showed greater preservation of renal function and
less kidney growth in patients who drank coffee compared to patients who did not. Thus, the evidence
derived from our prospective longitudinal study, that allows more confidence for causal inference than
previous in vitro or cross-sectional studies, does not support coffee drinking as a risk factor for ADPKD
progression. The aim of the second study was to develop a triage test that identifies patients currently not
meeting minimal TKV thresholds required for tolvaptan treatment and in whom TKV measurement can
be avoided. This study addresses the challenge in ADPKD management that channels every patient to
magnetic resonance imaging (MRI) or computer tomography (CT) to determine TKV, which is required
to determine the indication for tolvaptan. TKV is accurately measured by MRI, but the procedure is
costly and not available everywhere. To our knowledge, there is no available low cost triage test for
patients with ADPKD. We developed a simple triage tests based on commonly available demographic
and laboratory data using regression models and performed a diagnostic test accuracy study using data
from 204 patients enrolled in the Swiss ADPKD study. A sequential triage test reached a sensitivity of
over 90%. A triage test for MRI-based TKV measurement supports clinical decision making for better
resource allocation. The third study is the first external validation of the well-known Mayo Clinic models
for predicting disease progression in ADPKD. Prediction models in ADPKD are useful in clinical settings
for identifying patients with greater risk of rapid disease progression for whom a treatment may have
more benefits than side-effects. The Mayo Clinic investigators developed a risk prediction tool for patients
with ADPKD using a single TKV value. Our geographical and temporal external validation of the two
Mayo Clinic models suggest that these models are generalizable to clinical settings with a high predictive
performance and that the Mayo Clinic prediction model is an accurate tool with easily available predic-
tors for identifying patients at high risk for rapid disease progression. Adding additional information on
TKV did not improve the predictive performance to a meaningful extent. The three studies of this PhD
thesis contribute to the major therapy goal of slowing down disease progression. The triage tests and
prediction models developed and validated here support patient and physician evidence-based decisions
on the use of diagnostic imaging and on the indication of non-drug and drug therapies. The results of this
thesis open the door for the judicious use of expensive imaging tests and novel treatments. Additional
studies in this area including randomized trials and cost-benefit analyses for estimating benefits, harms
and cost of various testing and treatment pathways will ultimately inform clinical practice on the best
management strategies that optimally balance benefits, harms and cost of patients with ADPKD.
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Zusammenfassung 
Die autosomal dominante polyzystische Nierenerkrankung (ADPKD) ist die häufigste 
monogen vererbbare Nierenerkrankung und etwa 50% der betroffenen Patienten werden 
zwischen dem 50. und 60. Lebensjahr nierenersatzpflichtig. Ein zentrales Therapieziel ist die 
Verlangsamung der Krankheitsprogression, wofür einerseits die Krankheitsprogression 
prognostiziert werden und anderseits entsprechende Massnahmen für das ADPKD 
Management getroffen werden müssen. Im Jahr 2016 wurde das erste Medikament Tolvaptan 
zur Verlangsamung der Krankheitsprogression für einen schweren Verlauf zugelassen 
(Schweiz). Bis dahin konnten nur Begleiterkrankungen behandelt werden und daher waren 
Anpassungen des Lebensstils umso wichtiger für das ADPKD Management. Diese 
Dissertation beinhaltet drei Studien, welche zu einem evidenzbasierten ADPKD-Management 
beitragen. In der ersten Studie wurde der kausale Zusammenhang zwischen Kaffeekonsum 
und der Krankheitsprogression in der Schweizer ADPKD Kohorte untersucht. Die 
unaufhaltsame Progression von ADPKD hat viele Ärzte dazu veranlasst, eine Reduzierung 
von Risikofaktoren wie dem Kaffeekonsum zu empfehlen, dies trotz fehlender klinisch-
epidemiologischer Studien. Die Ergebnisse unserer Studie, welche die erste longitudinale 
Studie überhaupt ist, zeigten eine bessere Nierenfunktion und einen leicht milderen Abfall 
der Nierenfunktion bei ADPKD Patienten mit Kaffeekonsum im Vergleich zu ADPKD 
Patienten ohne Kaffeekonsum. Demnach bestätigen unsere Ergebnisse die in vitro Ergebnisse 
nicht, dass Kaffee ein Risikofaktor für einen schweren ADPKD Verlauf ist. In der zweiten 
Studie war es das Ziel, einen Triage Test zu entwickeln, der Patienten identifiziert, die noch 
unterhalb des Nierenvolumens liegen, welches zur Verschreibung des Medikaments 
Tolvaptan notwendig ist und damit unnötige MRTs vermieden werden können. Diese Studie 
adressiert die Herausforderung im ADPKD Management, dass derzeit bei allen Patienten eine 
Messung des totalen Nierenvolumens (TKV) mit Magnetresonanzbildgebung (MRT) 
durchgeführt werden müsste, um die Indikation für eine Therapie mit Tolvaptan zu 
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bestimmen. MRT-Untersuchungen sind jedoch teuer, erfordern spezifische Expertise bei der 
Analyse und sind daher nicht immer verfügbar. Daher entwickelten wir einen in der 
Anwendung einfachen Test basierend auf demographischen Angaben der Patienten und 
Labordaten von 204 Patienten der Schweizer ADPKD Kohorte mittels Regressionsmodellen 
und einer anschließenden Bewertung des diagnostischen Tests. Ein sequentielles Triage 
Testverfahren erreichte eine Sensitivität von über 90%. Der Triage-Test kann zu einer 
besseren Allokation der Ressourcen führen, da Patienten, die (noch) nicht für eine Therapie 
mit Tolvaptan qualifizieren, mit einfach zugänglicher Information zuverlässig identifiziert 
werden müssen, für die keine MRT-Untersuchung nötig ist. In der dritten Studie führten wir 
schliesslich die erste Validierungsstudie eines prominenten Vorhersagemodells für den 
Verlauf der ADPKD durch, welche von Wissenschaftler der Mayo Klinik entwickelt wurde. 
Ein Vorhersagemodell ist im klinischen Umfeld nützlich zur Identifikation von Patienten mit 
einem erhöhten Risiko für einen schweren Verlauf, bei denen eine aggressivere Behandlung 
trotz Nebenwirkungen indiziert sein kann. In unserer zeitlich - und räumlich externen 
Validierung der zwei Mayo Klinik Modelle zeigte sich, dass die Modelle auf eine wesentlich 
andere Population (Schweizer ADPKD Kohorte) generalisierbar sind und diese eine valide 
Methode darstellen, um Patienten mit einem zu erwartendem schweren Verlauf zu 
identifizieren. Ein erweitertes Modell mit zusätzlichen Informationen zum Nierenvolumen 
verbesserte die Vorhersagekraft des Modells nicht wesentlich.  
Die drei Studien dieser Dissertation tragen dazu bei, das zentrale Therapieziel der 
Verlangsamung der Krankheitsprogression zu verfolgen. Die hier entwickelten und 
untersuchten Triage-Tests und Vorhersagemodelle unterstützen evidenzbasierte Entscheide 
von Patienten und Ärzten zum Einsatz von aufwändigen diagnostischen Tests und zur 
Indikationsstellung von nichtmedikamentösen und medikamentösen ADPKD-Therapien.  
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Abstract 
Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic 
inherited renal cystic kidney disease and approximately 50 % of the patient’s progress to end 
stage renal disease between the 5th and 6th decade of their life. A major therapy goal is to 
slow down disease progression. To achieve this, it is necessary to predict disease progression 
and to implement ADPKD management that balances the benefits, harms and cost 
appropriately. In 2016, tolvaptan was approved as the first drug to slow down disease 
progression in ADPKD and it is indicated for patients with rapid disease progression in 
Switzerland. Before the availability of tolvaptan, treatment focused on managing co-
morbidities through medication and life style modification. This PhD thesis includes three 
studies, which contribute to an evidence-based management in ADPKD. The first study 
assessed the association between coffee consumption and disease progression in a 
longitudinal ADPKD cohort. The relentless progression of ADPKD means that most ADPKD 
experts are inclined to advocate the minimisation of risk factors for rapid disease progression 
such as caffeine consumption, despite the absence of clinical-epidemiological data indicating 
benefit. Our study results, which were, to our knowledge, based on the first longitudinal 
study that ensures temporality to assess the relationship between coffee consumption and 
disease progression, showed greater preservation of renal function and less kidney growth in 
patients who drank coffee compared to patients who did not. Thus, the evidence derived from 
our prospective longitudinal study, that allows more confidence for causal inference than 
previous in vitro or cross-sectional studies, does not support coffee drinking as a risk factor 
for ADPKD progression. The aim of the second study was to develop a triage test that 
identifies patients currently not meeting minimal TKV thresholds required for tolvaptan 
treatment and in whom TKV measurement can be avoided. This study addresses the 
challenge in ADPKD management that channels every patient to magnetic resonance imaging 
(MRI) or computer tomography (CT) to determine TKV, which is required to determine the 
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indication for tolvaptan. TKV is accurately measured by MRI, but the procedure is costly and 
not available everywhere. To our knowledge, there is no available low cost triage test for 
patients with ADPKD. We developed a simple triage tests based on commonly available 
demographic and laboratory data using regression models and performed a diagnostic test 
accuracy study using data from 204 patients enrolled in the Swiss ADPKD study. A 
sequential triage test reached a sensitivity of over 90%. A triage test for MRI-based TKV 
measurement supports clinical decision making for better resource allocation. The third study 
is the first external validation of the well-known Mayo Clinic models for predicting disease 
progression in ADPKD. Prediction models in ADPKD are useful in clinical settings for 
identifying patients with greater risk of rapid disease progression for whom a treatment may 
have more benefits than side-effects. The Mayo Clinic investigators developed a risk 
prediction tool for patients with ADPKD using a single TKV value. Our geographical and 
temporal external validation of the two Mayo Clinic models suggest that these models are 
generalizable to clinical settings with a high predictive performance and that the Mayo Clinic 
prediction model is an accurate tool with easily available predictors for identifying patients at 
high risk for rapid disease progression. Adding additional information on TKV did not 
improve the predictive performance to a meaningful extent. The three studies of this PhD 
thesis contribute to the major therapy goal of slowing down disease progression. The triage 
tests and prediction models developed and validated here support patient and physician 
evidence-based decisions on the use of diagnostic imaging and on the indication of non-drug 
and drug therapies. The results of this thesis open the door for the judicious use of expensive 
imaging tests and novel treatments. Additional studies in this area including randomized trials 
and cost-benefit analyses for estimating benefits, harms and cost of various testing and 
treatment pathways will ultimately inform clinical practice on the best management strategies 
that optimally balance benefits, harms and cost of patients with ADPKD.  
 
 7
Abbreviations  
 
ADPKD  autosomal dominant polycystic kidney disease  
cAMP  cyclic adenosine monophosphate  
CRPS  continuous ranked probability score  
CT  computer tomography 
eGFR  estimated glomerular filtration rate 
ESRD  end stage renal disease 
 
htTKV  height adjusted total kidney volume 
 
MRI   magnetic resonance imaging 
TKV  total kidney volume 
PKD   polycystic kidney disease  
RRT  renal replacement therapy 
 
 
 
 
 
 
 
 
 
 
 
 
 8
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 9
Contents 
 
 
 
Zusammenfassung 3 
Abstract 5 
Abbreviations 7 
Chapter I       General Introduction 11 
Chapter II  Long-Term Effect of Coffee Consumption on Autosomal Dominant Polycystic   
Kidneys Disease Progression: Results from the Suisse ADPKD, a Prospective 
Longitudinal Cohort Study 25  
Chapter III    Is a triage test for management TKV decision useful to select patients for a               
pathway in autosomal dominant polycystic kidney disease? 43 
Chapter IV    Temporal and geographical external validation study and extension of the 
Mayo Clinic Prediction Model to predict eGFR in the younger population of 
Swiss ADPKD Patients 65 
Chapter V      General Discussion 87 
Acknowledgements 97 
Appendix I:    Urinary Biomarkers at Early ADPKD Disease Stage 99 
Appendix II:   Chancen und Herausforderungen von Tolvaptan zur Behandlung von ADPKD 
–  Ein aktueller Stand der Entwicklung 129 
Other publications 135 
 
 
 
 10
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 11
 
Chapter I 
 
General Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 12
Introduction to Autosomal Dominant Polycystic Kidney Disease 
 
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a monogenic inherited 
renal cystic kidney disease that occurs in all races worldwide [1]. ADPKD is the most 
common hereditary kidney disease, with an estimated prevalence of 1 in 1000 cases in the 
general population, but with a lower prevalence of symptomatic ADPKD [2, 3]. It is 
characterised by the development of a multitude of renal cysts, which leads to massive kidney 
enlargement (Figure 1) [4]. Approximately 50% of patients develop end-stage renal failure 
(ESRD) between the fifth and sixth decade of life and ADPKD is the fourth leading cause for 
renal replacement therapy (RRT) [4], which includes dialysis or kidney transplantation.  
The pathogenesis of cyst formation begins in utero and the cysts enlarge continuously 
through the patient’s lifetime via an autonomous function in each cyst. The renal cysts are 
interspersed within fibrotic tissue. Intracellular 3′ 5′-cyclic adenosine monophosphate 
(cAMP) plays a major causative role in the pathogenesis and disease progression of ADPKD 
by stimulating transepithelial secretion, the accumulation of cyst fluid and cell proliferation. 
Competitively and non-selectively inhibitory cyclic nucleotide phosphodiesterases degrade 
the phosphodiester bond in the second messenger molecule cAMP. More than 10 years’ 
worth of research has revealed that increased levels of intracellular cAMP cause ADPKD 
progression by stimulating transepithelial secretion and cell proliferation [5, 6]. 
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Figure 1: MRI of an ADPKD-affected kidney with cyst formation from the Swiss ADPKD Cohort 
Study (green line: kidney contouring) 
 
 
The symptoms of ADPKD are correlated with renal enlargement. During a patient’s 
life, blood may accumulate in the renal cysts following trauma or pyrogenic infection. The 
majority of patients experience other symptoms such as kidney pain and gross haematuria. 
The associated comorbidities of patients with ADPKD are hypertension, urinary tract 
infection and proteinuria. Hypertension occurs in 50% of patients in the early disease group, 
i.e. those aged 20–35 years, and in 100% of patients with ESRD [7]. Cyst enlargement also 
occurs in the liver, with a prevalence of 95% (by the age of 35 years) [8]. 
In almost all patients, the pathogenesis of ADPKD stems from a mutation of the genes 
encoding for the proteins polycystin-1 (PKD1) and polycystin-2 (PKD2). PKD1 is located on 
chromosome 16 and its mutation is found in 85% of cases. PKD2 is located on chromosome 
4 and its mutation is found in around 15% of ADPKD cases [9, 10]. These mutations lead to 
the formation of distinctive fluid-filled renal cysts. Thus far, the mutations are not detected in 
around 1% of patients [11]. The clinical diagnosis of ADPKD in subjects with positive family 
history is confirmed when the number of cysts meet the Pei-Ravine diagnostic criteria for 
ADPKD [12, 13]. The Pei-Ravine criteria for ADPKD diagnosis specify age-dependant 
threshold for the number of cysts. 10-20% of the patients may not show a positive family 
history [14]. Genetic testing as a diagnostic test is useful when imaging cannot clearly 
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identify disease or for very early diagnosis in childhood. Two methods are used for ADPKD 
DNA-testing in equivocal cases: linkage analysis and direct mutation screening [15].  
 
Current ADPKD Management 
The main therapy goal in ADPKD is to slow down disease progression. In order to 
achieve this goal, clinicians need to predict the course of disease in an individual, use 
relevant outcomes to monitor disease progression, judiciously use imaging tests and pursue a 
decision making strategy that supports both non-drug and drug therapies options for patients.  
 
Estimating prognosis in ADPKD 
Prediction models in ADPKD are useful in clinical settings to inform patients about 
their prognosis and to support evidence-based decisions for risk-stratified treatment strategies 
where new therapies like tolvaptan are effective but have notable adverse effects. Patients 
with a slow disease progression might not need certain therapies or be best served by waiting 
until at a later disease stage for treatment. A few risk prediction models have been developed 
to support patients risk assessment: The Mayo Clinic Model [16] and the PROPKD-Score 
[17]. The major outcomes of relevance for ADPKD predictions models are End Stage Renal 
Disease (ESRD), total kidney volume (TKV) and estimated glomerular filtration rate 
(eGFR)[18], which form the basis for clinical determination of progression. In Europe, the 
average age for progression to ESRD is approximately 58 years [19]. Consistent and strong 
predictors of these outcomes include age, sex, TKV and eGFR at baseline as well as the 
Polycystic Kidney Disease (PKD)-genotype [20, 21].  
 
Measuring relevant outcomes in ADPKD  
The main outcomes in ADPKD are total kidney volume (TKV) and kidney function, 
estimated by the glomerular filtration rate (eGFR), which are indicators for disease severity 
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and progression. TKV is widely accepted as the main indicator for ADPKD progression. 
TKV is assessed by computer tomography (CT), the less sensitive renal ultrasonography or 
Magnetic Resonance Imaging (MRI), which is the gold standard, and it is used to measure the 
different size and volume parameters of the kidney. MRI, the preferred method for measuring 
TKV, can detect small cysts without requiring the use of ionizing or contrast media [16]. 
However, the measurement of kidney volume using MRI or CT is still not feasible for routine 
care in some countries (e.g. Australia, some countries in Europe) [22, 23]; therefore it is not 
available to a broad range of patients. The quality of the MRI depends on patient compliance 
and on various parameters, such as image sequences and slice thickness [24]. The state-of-
the-art method for kidney volume computation is hand-contouring of the whole kidney, 
which is greatly time- and cost-intensive given the high technical expertise required, and this 
modality is still not routine in clinical practice. Two methods for estimating TKV: the 
eTKVellipsoid and the eTKVPANK, which require less time than hand contouring, have 
been developed [25]. While eTKVellipsoid measurement of the TKV is very accurate and 
convenient [26], the high expenses of performing MRIs and the reimbursement policies of 
the healthcare system may result in limited access to repeated MRIs for selecting patients for 
a new treatment as well as for detecting change in TKV [23, 27]. 
Sequential TKV measurement is a dynamic biomarker of disease progression with 
sufficient precision to detect changes over a period as short as 6 months [28]. TKV is used to 
monitor treatment effects, but TKV estimations are still limited. The strongest predictors of 
disease progression are: Annual rate of TKV growth, age, baseline glomerular filtration rate, 
gender and PKD genotype. Increased kidney size is associated with pain, gross haematuria 
and proteinuria [16]. 
Kidney function (eGFR) is very stable for a long period and serum creatinine levels 
only increase once there is serious and irreversible damage to the kidneys. The GFR is a late 
marker of disease. Therefore, renal function for disease progression is less indicative for 
 16
evaluating progression at early disease stage because it decreases exponentially with 
advanced age. Kidney enlargement eventually results in a decline in renal function. 
Historically, the true GFR is the average urinary inulin clearance measured over a period of 
24 hours [29]. Three measurement methods have been developed to estimate GFR more 
easily, because in clinical practice it is not possible to measure eGFR over a 24-h period. 
Among them, the gold standard is Cr-EDTA or DTPA, often referred to as measured GFR 
(mGFR), where the clearance of iohexol or iothalamate is measured as filtration marker over 
a shorter period [30]. The second method is assessing the 24-hour clearance of creatinine or 
urea. This method is thought unreliable because creatinine clearance overestimates the true 
GFR and urea clearance underestimates the true GFR [31]. The third method is the use of an 
equation to estimated eGFR such as the MDRD (Modification of Diet in Renal Disease) or 
the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [32, 33, 34]. 
The CKD-EPI formula, which is the approach used most often in clinical practice, 
incorporates the variables serum creatinine, age, sex and race [34]: 
eGFR = 141 × min (Scr/Κ, 1)α × max (Scr/ Κ, 1)-1.209 × 0.993Age × 1.018 [if female] × 1.159 
[if black] 
Where Scr is serum creatine in mg/dL, K is 0.9 for males and 0.7 for females, and α is -0.411 
for males and -0.329 for females. 
 
Treatments options for ADPKD 
Lifestyle factors are particularly important for the management of ADPKD patients 
for reducing risk factors and strengthening resources that can help prolong and stabilise renal 
function until ESRD. Therefore, behaviour modification has been credited with delaying 
disease progression in patients with ADPKD in the past. Avoiding high sodium/salt intake, 
avoiding smoking, low alcohol intake, reduced coffee intake, exercise, maintaining hydration 
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and healthy diet are relevant lifestyle factors for ADPKD [35]. Until recently, no disease-
modifying therapy for treating ADPKD could prevent cyst formation and delay disease 
progression; only comorbidities could be treated [35]. General renoprotective treatment as 
such a low-protein diet, renin–angiotensin–aldosterone system inhibition and management of 
blood pressure control does not affect renal function decline in patients with ADPKD [36-
39]. Over the years, several disease-modifying therapies have been tested in ADPKD. Based 
on the results of the TEMPO 3:4 trial, the 2016 approval of tolvaptan, a vasopressin V2 
receptor antagonist that directly slows progression, heralded the first effective treatment for 
ADPKD [40]. The randomised, controlled TEMPO 3:4 trial involved 1445 patients with 
ADPKD with TKV > 750 mL and retained renal function over a follow-up duration of 3 
years. The results showed that tolvaptan reduced the TKV growth rate by 49% and the eGFR 
decline rate by 26%. Vasopressin is a synthetic aquaretic, therefore it induced the main side 
effect of polyuria of up to 6–8 L per day. The indication for tolvaptan is currently limited to 
patients with evidence of rapid progression[41] where the expected benefit outweighs the risk 
of adverse effect and associated high treatment costs[42]. It is currently not clear yet how 
rapid disease progression should be determined. 
 
Challenges and opportunities for the management of ADPKD 
There are a number of challenges but also opportunities in ADPKD that will be addressed 
in this thesis: 
1. Evaluate lifestyle factors such as coffee consumption that impact on disease 
progression in patients with ADPKD and that may be targeted to slow down disease 
progression 
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2. Evaluate which patients need elaborate imaging to determine rapid disease 
progression and develop tools for TKV-based management decisions for patients with 
ADPKD  
3. Support the balancing of benefits and harms of interventions by the use of valid 
prediction models that predict disease progression 
 
Effect of coffee for disease progression in an ADPKD cohort 
  Currently, there is a lack of evidence-based information about the effect for coffee for 
rapid disease progression. There is a requirement for greater understanding of the effect of 
coffee to optimise evidence-based management in ADPKD. The continuous progression of 
ADPKD and the lack of effective therapies until recently gave physicians and researcher little 
else to offer but strategies like minimization of caffeine consumption despite the absence of 
clinical and epidemiological data supporting their advice. In vitro results reported that 
caffeine activated pro-proliferative signalling pathways and increased transepithelial fluid 
secretion in murine PKD cells and the study concluded that caffeine is a risk factor for the 
promotion of cyst enlargement in patients with autosomal dominant polycystic kidney disease 
(ADPKD) [27]. Since then, many ADPKD experts have advocated minimizing caffeine 
intake. However, there is little evidence on the effect of caffeine in patients with ADPKD and 
only cross-sectional studies have been presented in the literature.  Since the current evidence 
base is very weak, there is a need for prospective and longitudinal studies to assess if there is 
a causal link between coffee consumption and disease progression.  
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A tool for TKV-based management decisions for ADPKD patients would be attractice 
Measuring TKV and TKV rate change as a surrogate for disease burden and 
progression has become even more important since the approval of tolvaptan in Switzerland. 
Based on the result of the TEMPO 3:4 trial, tolvaptan has been approved for those with a 
minimal TKV threshold and signs of rapid ADPKD progression [40]. Regulatory authorities 
have defined treatment eligibility as a TKV of at least 750 mL or a change in TKV of at least 
5% [43]. However, accurate assessment of TKV, which is generally determined based on 
MRI imaging [26], is costly, requires expertise and is limited by health insurance 
reimbursement policies [23, 27]. This is an opportunity to develop a more low-cost, easily 
implementable tool for TKV-based management decisions to identify patients, who are 
unlikely to meet minimal TKV thresholds for treatment with tolvaptan and for whom 
unnecessary expenses could be spared.   
Informing treatment decision through prediction models 
Information about prognosis in ADPKD is essential for clinicians to inform patients 
about their further prognosis. Prediction models combine several patient characteristics and 
additional tests to predict the risk of a defined outcome. Prediction model in ADPKD 
supports evidence-based decision for risk-stratified treatment who might benefit more from 
new therapies such as tolvaptan, which is indicated for patients with evidence of rapidly 
progressing disease [41]. This treatment brings us the challenge to identify which patients we 
should treat and when should start the treatment of those patients. Patients with a slow 
disease progression might not need a therapy now or only at a later stage. In 2016, the ERA-
EDTA Working Group outlined an algorithm for defining rapid disease definition in patients 
with ADPKD (Figure 4), which included the Mayo Clinic prediction model for classifying 
patients at high risk for rapid disease progression [23]. 
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Figure 2: A convergence for an algorithm for defining rapid disease definition in patients with 
ADPKD, adapted and modified from [23]. CKD (chronic kidney disease); TKV threshold used in 
Switzerland for tolvaptan indication. 
 
 
 
The Mayo Clinic investigators developed a risk prediction tool for ADPKD patients 
using a single TKV value and age at baseline [16, 44]. However, the prognostic performance 
of the prediction model has yet to be evaluated in an external population outside the US, 
which is critical for establishing accuracy and generalizability of risk discrimination across 
different patient populations [16]. Additionally, there is an opportunity to evaluate whether 
an improvement of the prediction performance could be achieved by including additional 
measurements.  
 
Rapid progression
• 18–30 yr: CKD 1–3a, or
• 30–40 yr: CKD 2–3a, or
• 40–50 yr: CKD 3a, or
• TKV > 750 mL
•with a eGFR decline >5 mL in 1 year, or
• eGFR decline > 2.5 mL in 5 years, or
• TKV increase > 5% per year
Likely rapid progression
• 18–30 yr: CKD 1–3a, or
• 30–40 yr: CKD 2–3a, or
• 40–50 yr: CKD 3a, or
•• TKV > 750 mL
• with Mayo classification: 1C-E, or
• truncating PKD1 mutation with early symtoms 
Possible rapid progression
• 18–30 yr: CKD 1–3a, or
• 30–40 yr: CKD 2–3a, or
• 40–50 yr: CKD 3a, o3
•TKV > 750 mL
• with family history with ADPKD, patients developing ESRD < 58 yr
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Outline of the thesis  
 
This PhD thesis contributes evidence on the management of ADPKD patients and 
addresses clinically relevant questions. Chapter II contains a paper focused on the effect of 
coffee consumption on ADPKD progression as assessed in a prospective and longitudinal 
cohort study of patients with early ADPKD. Chapter III focuses on a triage test for TKV-
based management decisions for patients with ADPKD. The aim of that study is to develop a 
triage test that identifies patients currently not meeting minimal TKV thresholds required for 
tolvaptan treatment and in whom TKV measurement can be avoided. In chapter IV, we report 
the performance of an independent geographical and temporal external validation of the two 
Mayo Clinic models and the exploration of an updating strategy for improving the predictive 
performance by adding additional information on TKV. Finally, chapter V summarises the 
main results of the previous chapters and discusses their potential implications for clinical 
practice and research.  
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Abstract 
Background: Previous in vitro experiments of human PKD cells reported that caffeine is a 
risk factor for the promotion of cyst enlargement in patients with Autosomal Dominant 
Polycystic Kidney Disease (ADPKD). The relentless progression of ADPKD inclined the 
majority of physicians to advocate minimization of caffeine consumption despite the absence 
of clinical data supporting such a recommendation so far. This is the first clinical study which 
assessed prospectively the association between coffee consumption and disease progression 
in a longitudinal ADPKD cohort.  
Methods: Information on coffee consumption and disease progression was collected at each 
follow-up visit using standardized measurement methods. The main model for the outcomes 
kidney size (htTKV) and kidney function (eGFR) was a linear mixed model. Patients entered 
to the on-going Swiss ADPKD study between 2006 to June 2014 and had at least one visit 
every year. The sample size of the study population was 151 with a median follow-up of 4 
visits per patient and a median follow-up time of 4.38 years. Results: After multivariate 
adjustment for age, smoking, hypertension, sex, body mass index and an interaction term 
(coffee*visit), coffee drinkers did not have a statistically significantly different kidney size 
compared to non-coffee drinkers (difference of -33.03cm3 height adjusted TKV, 95% CI 
from -72.41 to 6.34, p=0.10). After the same adjustment, there was no statistically significant 
difference in eGFR between coffee and non-coffee drinkers (2.03 ml/min/1.73m2, 95% CI 
from -0.31 to 4.31, p=0.089).  
Conclusion: Thus, data derived from our prospective longitudinal study does not confirm that 
drinking coffee is a risk factor for ADPKD progression.   
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Introduction 
Belibi and colleagues reported 2002 results derived from in vitro experiments of 
human PKD cells exposed to caffeine [1]. Caffeine activated pro-proliferative signalling 
pathways and increased transepithelial fluid secretion in murine PKD cells and the authors 
concluded that caffeine is a risk factor for the promotion of cyst enlargement in patients with 
autosomal dominant polycystic kidney disease (ADPKD) [2].  Caffeine raises intracellular 
adenosine 3':5’-cyclic monophosphate (cAMP) levels by competitively and non-selectively 
inhibiting cyclic nucleotide phosphodiesterases. These groups of enzymes degrade the 
phosphodiester bond in the second messenger molecules cAMP. For more than 10 years, 
intensive research has revealed that increased levels of intracellular cAMP causes ADPKD 
progression by stimulating trans-epithelial secretion and proliferation, thus further fostering 
the persuasion that caffeine consumption accelerates ADPKD progression [3, 4]. Since then, 
ADPKD experts and ADPKD patient organizations have advocated to minimize caffeine 
intake. 
 
However, there is little evidence on the effect of caffeine in patients with ADPKD and 
only cross-sectional studies are available so far. In 2012 the results of a cross-sectional study 
in ADPKD and healthy volunteers investigating the difference in caffeine intake and renal 
volume were reported [5]. Vendramini and colleagues did not identify an association of 
caffeine intake and kidney size, whereas the intake of caffeine was much lower among 
ADPKD patients than in healthy volunteers. Possibly the observed caffeine consumption 
difference among ADPKD patients and healthy volunteers was due to the conviction in the 
ADPKD community that caffeine might be toxic for ADPKD patients, although these 
concerns were based solely on in vitro human cell experiments [6].  
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The relentless progression of ADPKD and the lack of effective therapies until recently 
inclined the majority of physicians to advocate minimization of caffeine consumption despite 
the absence of clinical data supporting their advice. In fact, cohort studies in human beings 
repeatedly showed a beneficial effect of coffee consumption on various outcomes. Coffee 
consumption has been associated with decreased mortality in a meta-analysis of nearly one 
million subjects in 21 different independent studies [3, 7]. Coffee drinking’s beneficial 
effects have been identified for various diseases including cardiovascular and kidney diseases 
[8-10].  
Since the current evidence base is very weak, our aim was to assess the longitudinal 
association of coffee consumption and the progression of disease in patients affected by 
ADPKD. 
 
Methods 
Study Design and Participants  
Patients were eligible for our analysis if they were enrolled from 2006 to 2014 in the 
Swiss ADPKD cohort and if they had not been treated with possible disease modifying drugs 
(e.g. Sirolimus, Everolimus, Tolvaptan, Somatostatin analogues). Patients had a proven 
ADPKD diagnosis, were between 18 and 60 years old and had an eGFR over 30 ml per min 
per 1.73m2 at enrolment to the cohort. All patients provided a written informed consent and 
the local ethic committee approved the study (EK-number 1178). Possible serious adverse 
events and adverse events have been reported to the investigator of the study at least at every 
study visit. The included patients had a minimum of 1 and a maximum of 8 follow-up visits 
(median: 4 visits) and a median follow-up time of 4.38 years (IQR: 2.16 to 6.1 years). At 
each study visit the medical history was obtained, including medication, complications 
related to ADPKD, and the daily consumption of caffeine [11]. We excluded 69 patients with 
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less than 2 visits because our study focused on disease progression over time, leading to a 
total sample size of 151 patients with 687 observations. 
 
Progression of disease 
 Our primary outcome for progression of disease was kidney size by using height 
adjusted total kidney volume (htTKV) and the secondary outcome was the glomerular 
filtration rate (GFR). The baseline visit and each follow-up visit included a measurement of 
the kidney size and function by using a standardized procedure protocol. The Magnetic 
Resonance Imaging acquisition consists of breath-hold T1-weighted fast spoiled gradient 
echo sequence without fat suppression sequence (4 mm slice thicknesses) and a trans-axial 
T2 weighted fast spin echo sequences. The total kidney volume was estimated by hand 
contouring of all MRI slices. The observer was blinded for previous measurements. Manual 
volume segmentation was done with the computer workstation advantage windows 
workstation 4.4, GE Healthcare[12]. At each study visit, serum creatinine with the use of the 
modified Jaffé method traceable to an isotope-dilution mass spectroscopy reference was 
assessed[13]. GFR was estimated by applying the CKD-EPI formula[14]. 
 
Coffee consumption  
       Coffee consumption was assessed at each visit according to the following categories: 
Never drinking coffee; less than one cup of coffee per day, one or two cups of coffee per day, 
two to four cups of coffee per day, and more than four cups of coffee per day. For the 
analysis, coffee consumption was summarised in a binary variable, as “No drinking or less 
then one coffee a day” and “coffee drinkers”. If the information about coffee consumption 
was missing for a certain visit (number of missing values: 162), the last available information 
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was used for the analysis. We also performed a sensitivity analysis without imputation of 
missing values.  
 
Potential confounders 
We considered the following potential confounders in the analyses that may bias the 
association of coffee consumption and progression of ADPKD: At each visit, anthropometric 
measurement and laboratory examinations were performed including height-, weight- and -
blood pressure measurement as well as various blood and urine analysis. BMI (kg/m2) was 
included as a continuous variable. Blood pressure was measured in a sitting position, two 
times at an interval of 10-minutes, by using an oscillometric blood pressure device (Boso-
Medicus, Jungingen, Germany). The variable hypertension was defined as either systolic 
blood pressure above 140 mmHg, diastolic blood pressure above 90 mmHg and/or taking 
antihypertensive medication. Smoking was summarised in a binary variable, as “yes” and 
“no”.  
 
Statistical Analysis  
           Baseline characteristics are given as proportions, means (± standard deviation) and 
median (interquartile range, IQR), depending on their distribution. The main model for the 
primary outcome kidney size (htTKV) was a linear mixed model, with htTKV as outcome 
and coffee consumption as exposure, and adjustment for confounders (baseline age, sex, 
hypertension, smoking and BMI). We included a random intercept for each subject and a 
random slope for each subject over time in the mixed model. Most of the covariates were 
time-varying (coffee, hypertension, smoking and BMI) except of two which were fixed 
(baseline age and sex) [15]. Mixed models allowed us to track subject-specific change over 
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time and take into account the fact that data from the same individual are not independent. P-
values of <0.05 were considered significant. Stata 13.1 was used for data analysis.  
 
Results 
Patient characteristics 
          At inclusion (from April 2006 to June 2014) all 220 patients had a proven ADPKD 
diagnosis. The remaining 151 ADPKD patients with 687 observations were included in the 
analyses. At baseline, 101 (67%) patients were coffee drinkers whereas 50 (33%) patients did 
not drink coffee. Their overall mean ± SD age was 32.8 ± 8.9 years, and 60 (40%) were 
female. Non-coffee drinkers compared to coffee drinkers (Table 1) were younger (28 ± 8 
years vs. 35 ± 8 years), their kidneys at baseline were smaller (753 cm3 vs. 1118 cm3), and 
their renal function was better (eGFR 95.8 ± 19.5 ml/min/1.73m2 vs. 88.2 ± 19.1 
ml/min/1.73m2). The majority of patients suffered from hypertension (26 (52%) of the non-
coffee drinkers and 69 (68%) of the coffee drinkers).  
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Table 1. Demographic, clinical, and laboratory data at enrolment (baseline) according to 
coffee consumption group  
Characteristic Total 
N=151 
No Coffee drinkers  
N=50 
Coffee drinkers 
N=101 
Age – years  32.8 ± 9 27.92 ± 8 35.2 ± 8 
Sex – no. (%)     
Female 60 (40) 23 (46) 37(37) 
Male 91 (60) 27 (54)  64 (63) 
BMI – kg/m2 (Mean± SD) (Missings=9) 24.04 ± 4 23.62 ± 4 25.38 ± 4 
eGFR – ml/min/1.73m2  (Missings=2) 
Mean± SD 
Median (IQR)  
 
90.78 ± 19 
89.24 (78 to 104) 
 
95.8 ± 19 
97.01 (82 to 113) 
 
88.23 ± 19 
87.04 (75 to 102) 
Smoking – no. (%) 53 (36) 16(33) 37 (37) 
TKV – cm3   
Mean± SD 
Median (IQR) 
 
1050.8± 685 
894.51 (576 to 1306) 
 
915.8± 632 
752.56 (492 to 1038) 
 
1117.8 ± 703 
976.43(603 to 1372)
htTKV – cm3/m 
Mean± SD) 
Median (IQR) 
 
595.9 ± 382 
504.56 (333 to 732) 
 
519.3±364 
421.7 (268 to 613) 
 
633.9± 87 
549.03 (353 to 762) 
Hypertension   – no. (%) 95 (63) 26 (52) 69(68) 
Blood pressure – mmHg (Missings=2)    
Systolic  (Mean± SD)  138.4 ± 14 136.5± 13 139.4 ± 15 
Diastolic (Mean± SD)  89 ± 10 86.2± 9 90.5 ± 11 
Antihypertensive Drug – no. (%) 107 (71) 32 (64) 75 (74) 
    
 
Association of coffee consumption with kidney progression 
We found in the adjusted mixed model for height adjusted TKV (htTKV) a smaller 
estimated kidney size among coffee drinkers compared to non-coffee drinkers ([beta]Coffee = -
33.13; 95% CI from -72.52 to 6.34; p=0.10) but the difference was not statistically 
significantly different. The interaction term between coffee and time in years was also not 
statistically significant ([beta]Coffee*Visityr = 10.85; 95% CI from -1.89 to 23.58; p=0.10), 
indicating only week evidence for a steeper increase of htTKV in coffee drinkers over time. 
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The time variable was significant in all analyses ([beta]Visityr = 49.32; 95% CI from 35.49 to 
63.10; p=<0.01). Fig 1 illustrates the development of htTKV over time from the mixed model 
taking into account an interaction between time (in years) and coffee. The lower baseline 
values of  coffee drinkers as well as the steeper slope over time are clearly visible. 
 
Fig 1. Adjusted prediction of kidney size (height adjusted total kidney volume (htTKV)) with 
95% CI, by coffee consumption group 
 
A sensitivity analysis included the alternative time variable “number of visits since 
enrolment” instead of time in years and “age” as time-varying covariate (instead of age at 
baseline) and showed similar results (Table 2) as the main model. A repetition of the analysis 
for subjects with more than 2 visits (omitted if < 3 visits per subject) confirmed our results.   
An additional sensitivity analysis without imputation of missing values for coffee showed 
similar results and confirmed the main analysis (Supplementary data table 1).   
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Table 2. Association of coffee consumption with adjusted kidney size (height adjusted total 
kidney volume (htTKV)) over time (N=148) 
        Main Analysis: htTKV with visit in years and baseline age 
Fixed effects 
    Name  Coefficient p-Value 95% -CI 
(Intercept) 222.19 0.14 from -76.86 to 521.25 
Coffee -33.13 0.10 from -72.52 to 6.34 
Visityr 49.32 <0.01 from 35.49 to 63.10 
CoffeeVisityr 10.85 0.10 from -1.89 to 23.58 
Sex -204.56 <0.01 from -316.18 to -91.19 
Age Baseline 17.30 <0.01 from 11.25 to 23.67 
BMI 4.78 0.08 from -0.57 to 10.14 
Hypertension -13.01 0.27 from -36.55 to 10.42 
Smoke -6.27 0.59 from -29.27 to 16.72 
Random Effect    
Group  Name Variance 
Patno (Intercept) 333.75 19.72 
Visityr  59.05 3.93 
Residual  47.43 1.77 
 
Sensitivity Analysis: htTKV with visit number and age (time-dependent) 
Fixed effects 
      Name  Coefficient p-Value 95% -CI 
(Intercept) -2.67 0.99 from -296.45 to 291.10 
Coffee -66.63 0.02 from -123.85 to -9.42 
Visite (Nr) 12.67 0.01 from 2.73 to 22.61 
CoffeeVisit 10.17 0.03 from 1.07 to 19.26 
Sex -189.02 <0.01 from -297.85 to -80.20 
Age 24.60 <0.01 from 18.93 to 30.27 
BMI 3.41 0.28 from -2.78 to 9.60 
Hypertension -13.95 0.33 from -42.06 to 14.17 
Smoke -7.32 0.61 from -35.17 to 20.54 
Random Effect    
Group  Name Variance 
Patno Intercept 318.12 19.90 
Vist (Nr)  36.00 2.42 
Residual  57.43 2.16 
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Association of coffee consumption with eGFR 
The main mixed model for eGFR was adjusted for the same confounders as the model 
for htTKV (Table 3). We can see that eGFR was estimated to be higher among coffee 
compared to non-coffee drinkers (2 ml per min per 1.73 m2 ([beta]Coffee = 2.03; 95% -0.31 to 
4.38, p=0.089), however, this effect was again not statistically significant. Fig 2 illustrates 
our mixed model’s adjusted predictions of eGFR with 95% CI. 
 
Fig 2. Adjusted prediction of kidney function  (estimated glomerular filtration rate (eGFR)) 
with 95% CI, by coffee consumption group 
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Table 3. Adjusted association of coffee consumption with kidney function (estimated 
glomerular filtration rate ml/min/1.73 m2 (eGFR)) over time (N=148) 
        Main Analysis: eGFR with visit in years and baseline age  
Fixed effects 
      Name  Coefficient p-Value 95% -CI 
(Intercept) 140.67   <0.01 from 124.38 to 156.96 
Coffee 2.03 0.089 from -0.31 to 4.38 
Visityr -2.13 <0.01 from -2.67 to -1.59 
Sex 0.48 0.854 from -4.69 to 5.67 
Age Baseline -1.34 <0.01 from -1.62 to -1.05 
BMI -0.17 0.418 from -0.58 to 0.24 
Hypertension -3.56 <0.01 from -5.98 to -1.15 
Smoke -1.81 0.141 from -4.22 to 0.59 
Random Effect    
Group   Name Variance 
Patno (Intercept) 14.35 0.92 
Visityr  2.44 0.23 
Residual 
 
6.21 0.22 
 
Sensitivity Analysis: eGFR with visit number and age (time-dependent)  
Fixed effects 
Name  Coefficient p-Value 95% -CI 
(Intercept) 142.86    <0.01 from 126.92 to 158.79 
Coffee 2.13 0.079 from -0.24 to 4.52 
Visit (nr) -0.46 <0.01 from -0.83 to -0.08 
Sex 0.08 0.975 from -5.04 to 5.21 
Age -1.37 <0.01 from -1.64 to -1.09 
BMI -0.18 0.385 from -0.59 to 0.23 
Hypertension -3.35 <0.01 from -5.78 to -0.92 
Smoke -1.51 0.223 from -3.93 to -0.92 
Random Effect    
Group  Name Variance 
Patno (Intercept) 13.97 0.93 
Visit (Nr)  1.56 0.14 
Residual  6.22 0.22 
       
 
The sensitivity analysis with the time variable number of visits since enrolment and 
adjusted for age as a time-varying covariate (instead of age at baseline) showed similar 
results as the main analysis. As in the former section, the analysis for subjects with more than 
2 visits (omitted if < 3 visits per subject) showed very similar results.  An additional 
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sensitivity analysis without replacing missing values for coffee confirmed the results of the 
main analysis (Supplementary data table 2).   
 
Discussion 
In our prospective longitudinal study of an ADPKD cohort at early disease stage, we 
did not find a statistically significant association between coffee consumption and disease 
progression as measured by kidney volume and function. The main analyses were 
corroborated by the sensitivity analyses, which assessed if results changed by including 
predictors for ADPKD progression as time-varying covariates. The examination of the 
relationships between htTKV and age as a time-varying covariate showed similar results for 
the slope whereas the interception point of the trajectory lines was higher, (approximately for 
4 visits). Our findings indicate that drinking coffee is unlikely to be a risk factor for disease 
progression in ADPKD patients. 
One may speculate if coffee consumption even has some protective effect. The point 
estimates for kidney volume and function favour the coffee consumption group although not 
statistically significantly so. The effect might change over time as Figs 1 and 2 show. The 
protective effect on kidney volume may diminish over time, whereas the effect of coffee 
consumption on kidney function was constant over time.  
 
In fact, cohort studies in human beings have well investigated the effect of coffee 
consumption on various outcomes and repeatedly showed a beneficial effect. A community-
based study from Hsu et al. has investigated risk factors for chronic kidney disease including 
coffee consumption. After adjustment, coffee consumption was associated with a lower risk 
of chronic kidney disease [16]. Three large cohort studies published in 2014 have 
investigated the association between coffee consumption and the incidence of kidney stones. 
Drinking coffee was independently associated with a lower risk of incident kidney                
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stones [17]. Coffee consists of more than caffeine, it is also rich in antioxidants, which has 
been attributed for many of its health benefits [18]. Previous studies reported that coffee can 
have a positive effect on health and is a protective factor on avoiding diabetes, cancer (skin, 
breast, neck and head), stress, Parkinson’s disease and also heart disease [8-10]. Besides 
these observations, other studies have also reported negative effects of coffee consumption on 
blood pressure, cholesterol, serum lipids levels, and insulin resistance [19-22]. A dose 
response meta-analysis of 21 longitudinal studies with nearly 10 000 00 subjects showed a 
non-linear association between coffee and mortality from all causes, cardiovascular disease 
and cancer. The highest risk reductions were observed by drinking 4 cups per day for all-
cause mortality and 3 cups per day for cardiovascular mortality. Drinking coffee was not 
associated with increased mortality due to cancer [7]. Therefore, transferring the strong 
evidence of a protective effect of a moderate coffee consumption from other diseases may 
imply, that drinking coffee may also be beneficial for ADPKD patients in general through 
antioxidant and anti-inflammatory effects. And indeed, our results contravene the general 
recommendation to avoid drinking coffee for patients affected by ADPKD.   
 
Currently, Tolvaptan as a disease modifying therapy is available in Japan, Canada, 
States and Europe, the latter of which has recently been approved [23]. Before, only co-
morbidities could be treated. Beside this new medical treatment, lifestyle factors are 
particularly important for ADPKD patients to reduce risk factors and strengthen resources 
that can help prolonging and stabilizing renal function until end stage renal disease (ESRD). 
Therefore, avoiding potential risk factors in lifestyle, have been attributed a relevant role to 
delay the disease progression in patients with ADPKD in the past.  
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Our results have to be interpreted in the context of the study design and setting. 
Firstly, one limitation is the measurement of coffee consumption as the only source of 
caffeine (e.g. no soda, black tea or energy drinks were evaluated). Although it is difficult to 
capture coffee consumptions differently, self-reported coffee consumption may be prone to 
misclassification, which may result in biased results. A limitation of our study is that self-
reported coffee consumption does not include other source of caffeine like cola, energy 
drinks and black tea. Secondly, the number of follow-up visits may still be too low and we 
may have missed important long-term effects. Moreover, our subjects did not routinely 
undergo genetic testing during the study visits. However, based on the mean annual kidney 
growth rate of 9.43 % and the median kidney size at baseline of 894.51 cm3, it is very likely 
that the vast majority of our patients have PKD1 mutations.  
 
Strengths of the presented study include its longitudinal design, the comprehensive 
statistical approach, the careful measurement of kidney volume and function and the well-
described cohort of untreated ADPKD patients at early disease stage. 
 
          We believe that our results are a major step forward to elucidate the role of coffee 
consumption in ADPKD patients. The current evidence in patients with ADPKD including 
this longitudinal study does not suggest an association between coffee consumption and 
disease progression. It may be too early to frame a recommendation for coffee consumption 
but it is time to at least lift the current recommendation to strictly avoid coffee consumption. 
In order to come up with stronger and evidence-based recommendations additional studies 
are needed to strengthen the causal inference on coffee consumption and disease progression. 
Additional prospective cohort studies would show how consistent the results are across 
studies, if there is a dose-response relationship, if there are subgroups of ADPKD patients 
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who have different effects of coffee consumption and if longer follow-up reveals a protective 
effect of coffee consumption. 
 
          In conclusion, this is the first prospective longitudinal study to investigate the long-
term effect of coffee consumption in an ADPKD population, carefully controlled for 
confounding. Our results suggest that drinking coffee is not a risk factor of ADPKD 
progression and question the current recommendations against coffee consumption. 
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Abstract 
Total kidney volume (TKV) is an important outcome for assessing disease severity in patients 
with autosomal dominant polycystic kidney disease (ADPKD). TKV has become the primary 
metric for assessing progression, as regulatory authorities have defined minimal TKV 
thresholds and TKV rate changes for determining eligibility for tolvaptan treatment. TKV can 
be accurately measured by magnetic resonance imaging (MRI); however, MRIs are costly 
and not universally available. The aim of our study was to develop a triage test to identify 
patients unlikely to meet minimal TKV thresholds required for tolvaptan treatment for whom 
TKV measurement via MRI can be avoided. We developed a simple triage test based on 
TKV estimation from generally available demographic and laboratory data.  Predictors for 
the estimation formula were selected using least absolute shrinkage and selection operator 
(lasso). We assessed the diagnostic accuracy of final triage algorithms using data from 204 
patients enrolled in the on-going Swiss ADPKD study to detect patients with TKV above 750 
mL. Two decision thresholds applied to estimated TKV values from two different models 
were evaluated for discrimination accuracy. A decision threshold of 750 mL with a 
parsimonious estimating equation resulted in a sensitivity of 82% while a decision threshold 
of 675 mL resulted in a sensitivity of 87%. Our results suggest that a diagnostic management 
strategy using standard clinical data as the basis for a triage test can support decision making 
and aid allocation of medical resources, potentially reducing medical costs and unnecessary 
imaging procedures. 
 
 
Keywords: ADPKD, chronic kidney disease, kidney development, vasopressin 
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Introduction 
 
Total kidney volume (TKV), a measurement of kidney size, is an accepted surrogate 
for disease severity and a common outcome measure in clinical trials evaluating treatment 
efficacy in patients affected by autosomal dominant polycystic kidney disease (ADPKD). 
Positive change in TKV over sequential measurements reflects cyst enlargement and thus 
TKV serves as a sensitive marker of disease progression [1-3]. Changes in kidney size of as 
little as 20 cm3 can be detected from repeated MRI measurements [4]. Thus while other 
predictors of disease progression exist including age, estimated glomerular filtration rate 
(eGFR) and Polycystic Kidney Disease (PKD)-genotype, TVK and its growth rate are 
considered the gold standard for defining ADPKD progression [1,5,6].  
Measuring TKV and TKV rate change as a surrogate for disease burden and 
progression has become even more important since the approval of tolvaptan, a vasopressin 
V2 receptor antagonist that slows disease progression. Based on the result of the TEMPO 3:4 
trial, tolvaptan has been approved in Canada, Japan, European Union and Switzerland for 
those with a minimal TKV threshold and signs of ADPKD progression [7]. Regulatory 
authorities have defined treatment eligibility as either: 1) a TKV of at least 750 mL or 2) a 
change in TKV of at least 5% [8]. Among ADPKD patients, the prevalence of TKV ≥750 mL 
was 58% in the CRISP Study [3] and 56% in the Swiss ADPKD Study, suggesting that 
approximately half of the current patient population may meet these eligibility criteria. 
However, accurate assessment of TKV, which is generally determined based on MRI 
imaging [9], is costly, requires interpretation expertise and is limited by health insurance 
reimbursement policies [10, 11]. Thus, the development of a low-cost, easily implementable 
triage test to identify patients who are unlikely to meet minimal TKV threshold for treatment 
with tolvaptan could prevent unnecessary expense and medical personnel time.  
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An optimal triage test would be based on easily obtainable parameters captured during 
regular care, have high sensitivity and at least moderate specificity. A high sensitivity would 
ensure that those most likely to qualify for tolvaptan treatment are selected for further testing 
(low false negative rate); a moderate specificity would reduce the number of unnecessary 
tests by removing most of the patients who are unlikely to qualify for treatment (modest false 
positive rate) [12, 13].  
 To our knowledge, there is no triage test for ADPKD patients, although the potential 
of such a decision tool for saving resources could be substantial, assuming a 50% prevalence 
of treatment eligibility in ADPKD patients aged 18 to 45 years. Therefore, the aim of our 
study was to develop a triage test based on TKV prediction from easy accessible clinical 
parameters to screen ADPKD patients for further MRI imaging and evaluate its performance 
given two proposed decision thresholds of 750 mL and 675 mL.  
 
 
Results: 
 
Baseline characteristics  
204 patients with ADPKD between April 2006 and October 2016 were included in the 
analysis. Forty-three patients with missing baseline information on TKV, eGFR and age were 
excluded. The median age at baseline was 33 years (interquartile range [IQR]: 26-39), the 
median eGFR at baseline was 82 mL/min per 1.73 m2 (IQR: 72-96) and the median TKV at 
baseline was 858 mL/m (IQR: 565- 1354) 
 
 
 
 
47
TKV estimation formula  
A total of 146 subjects with complete data for all 49 variables of interest were used in 
least absolute shrinkage and selection operator (lasso) regression to select important 
predictors of TKV. Table 2 shows the result for both a parsimonious estimating equation 
(basic equation) and an extended estimating equation (extended equation) for TKV.  
 
Estimation equation performance  
The basic equation had an R2 of 47%.  Fifty-two percent of the predicted TKV were 
within 30% of the true TKV and the RSME was 0.45. When additional blood parameters 
were included, the resulting extended equation had a modestly higher R2 of 52%, 55% of the 
predicted TKV values were within 30% of the observed TKVs and the RSME was 0.43. 
Table 3 shows the performance of the basic and extended equations (Supplement figure 1).  
The extended model had slightly improved concordance between the estimated and measured 
TKVs at 68% compared to 64% for the basic model. The bias (median difference) was also 
modestly reduced with the extended model.  
 
Performance of the triage test  
Using the basic equation, a decision threshold of 750 mL resulted in a sensitivity of 
82% and a specificity of 64% (table 4). Applying a lower decision threshold of 675 mL 
resulted in a sensitivity of 87% and a specificity of 53%. The area under the curve (AUC) for 
the basic equation was of 0.83 (Figure 1).  
When TKV was estimated with the extended equation, a decision threshold of 750 mL 
resulted in a sensitivity of 85% and a specificity of 64%. Applying a lower decision threshold 
of 675 mL resulted in a sensitivity of 92% and a specificity of 55% (Table 2,). The AUC for 
the extended equation was of 0.85 (Fgure 1).  
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Performance of a sequential test after 1-2 years of follow-up 
Given changes in the characteristics of the sample at a second testing time point, the  
TKV estimation model was refit and new parameter estimates were obtained for the 
covariates flank pain, macrohematuria and coffee consumption (supplementary data table 1). 
A basic formula for a second test using a decision threshold of 750 mL resulted in a 
sensitivity of 53% and a specificity of 96%. Applying a lower decision threshold of 675 mL 
resulted in a sensitivity of 64% and a specificity of 91% (table 4). 
Adding a second test and a maximum of 2 years of follow-up substantially improved 
overall sensitivity with the extended model and a threshold of 750 mL yielding an overall 
sensitivity of 92%. Using the more conservative threshold of 675 mL resulted in an overall 
sensitivity of 95%. Results were very similar for the basic model, with an overall sensitivity 
of 91% with a threshold of 750 mL and a sensitivity of 95% for a threshold of 675ml.  
 
Expected decision-making for a hypothetical population of 1000 patients  
Figure 2 shows the expected natural frequencies along each clinical pathway based on 
the four models. The basic equation with a threshold of 675 mL resulted in the detection of 
38 more true positives per 1000 patients compared to the threshold of 750 mL. The extended 
equation detected a higher numbers of true positive patients at both thresholds compare to the 
basic equation, but the conservative threshold of 675 mL resulted in 36 more true positives 
per 1000 patients compared to the threshold of 750 mL.  
Applying a second test 2 years later resulted in the detection of 59 additional true 
positives per 1000 patients with a threshold of 750 mL. Applying the more conservative 
threshold of 675 mL resulted in 46 additional true positive patients.  
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Discussion 
Here we evaluated the performance of a triage test for identifying ADPKD patients 
unlikely to meet minimal eligible criteria for tolvaptan treatment, as currently defined by care 
guidelines. We found that applying either a 750 mL or a 675 mL decision threshold to an 
estimated TKV yielded sensitivity of greater than 90% after sequential testing. A comparison 
of a basic and an extended TKV estimating equation indicated that age, height, eGFR, 
weight, sex, hypertension, coffee, blood pressure and presence of symptoms were sufficient 
indicators of TKV, and the addition of diastolic blood pressure (bpd), sodium, cholesterol, 
high density lipoprotein (hdl) and urea did not result in markedly improved predictive 
performance that would warrant the added requirement of availability of these laboratory 
measurements.  
 
Given the high sensitivity that can be achieved with a basic triage test using 
ubiquitously measured ADPKD disease indicators, such a procedure would be feasible to 
implement in routine ADPKD clinical care. There are cost and staff burden benefits of 
reducing the number of MRIs done on patients in care, even in clinical care centers with 
dedicated MRI acquisition protocols and trained personnel to measure TKV. To date, MRIs 
for assessment of TKV are not reimbursed in some countries (e.g. Australia) [10, 14]. A 
clinical decision-making tool for triaging patients towards or away from additional MRI 
screening could form the basis of a reimbursement policy. Furthermore, patients in countries 
with less developed health care systems could benefit from a more efficient allocation of 
MRI resources.  
 
An alternative measurement modality for TKV-based management decisions is 
ultrasound (US), which is mostly used for pre-symptomatic screening of individuals at risk 
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for ADPKD [15]. Measuring TKV via US does not reduce costs and the inter-operator 
variability has been found to be too high to allow short-term progression to be detected [16-
18]. For clinical trials [4] and drug prescription [19], precise measurement of TKV is 
required and can only be obtained by MRI or CT [20, 21]. Thus, US would not be a practical 
substitute [19].  
 
In applying decision thresholds, we assumed that modest numbers of false negatives 
were acceptable, as sequential testing would later detect these patients before much additional 
progression had occurred. However, there are costs in terms of patient quality of life and 
increased damage to the kidney associated with delay of treatment, which are difficult to 
quantify. A lower decision threshold may be more appropriate in contexts where additional 
MRIs are less burdensome.   
 
Additional studies are warranted to estimate the costs and benefits associated with a 
triage test.  Though a formal cost effectiveness analysis was beyond the scope of the current 
paper, at an approximate estimated billing costs of 850 $ per MRI suggest that the expected 
cost per 1000 patients of universal MRI imaging is $850’000, while the expected MRI costs 
under presented scenarios including a triage test ranged between $585’650 to $640’900 
(Figure 3). However, additional factors need to be considered, such as the impact of a 
delayed detection of disease stage and a later initiation of tolvaptan. There are also ethical 
considerations. Tolvaptan delays the progression to end stage renal disease by up to 120 days 
per year. Whether rationing treatment is reasonable and the ADPKD care community can 
justify limiting access to the benefit of therapy may continue to be debated. Certainly there 
are harms associated with tolvaptan use that warrant careful monitoring in treated patients.  
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In conclusion, a diagnostic management strategy using a triage test based on 
estimation of TKV can provide sufficient accuracy for better resource allocation; in contexts 
where additional MRIs are less burdensome a lower decision threshold may be more 
appropriate.   
 
Methods 
 
Study Participants  
The on-going prospective observational Swiss ADPKD study has been described 
previously [22-24]. For the current study, we included participants that were under active 
follow-up between 2006 and 2016, who had not yet been treated with tolvaptan. Patient visits 
occurred at the University Hospital in Zurich (USZ) and at the Hirslanden Clinic in Zurich. 
The local ethics committee in Zurich approved the study (EK-number 1178).  
 
Available clinical variables  
Data were available from clinical visits, which occurred at intervals according to 
clinical need. TKV was measured by using a standardized procedure protocol [25] TKV was 
estimated by hand contouring or by midslice method to estimate TKV after 2015 [26, 27]. At 
the baseline and follow-up visit, GFR was estimated using the CKD-EPI formula [28]. Blood 
pressure, height and weight were assessed at each visit, and both blood and urine samples 
were taken using standardized laboratory procedures.  
Hypertension was defined as either systolic blood pressure above 140 mmHg, 
diastolic blood pressure above 90 mmHg and/or antihypertensive medication use. Smoking 
was summarised in a binary variable, as current or former/never. Coffee consumption 
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(yes/no) was based on self-report. The presence of flank pain, macrohematuria or/and cyst 
infection were captured from a case report form completed during the clinical visit.  
 
Development of the triage test 
Using data from all participants with compete data on all clinical variables, Lasso 
regression was used to screen all available clinical measures to identify the strongest 
predictors of TKV. The Lasso operator adds a penalization term to the magnitude of the 
regression coefficient and minimizes the sum of errors towards zero [29]. Parameter 
estimates from linear regression for the outcome of natural log of TKV were evaluated for 
inclusion in the final TKV estimation formula. Out of the Lasso regression, we included the 
variables bpd sodium, cholesterol, hdl and urea on the natural scale into the model; blood 
haemoglobin was left out because of too little additional added value. In addition, we 
developed a basic model for estimating log TKV, which included only the baseline predictors 
age, height, eGFR, weight, sex, hypertension, coffee and symptoms.  
For the sequential second test in the testing pathway, we refit the TKV estimating 
equation and included for the outcome log TKV the parameter estimator’s eGFR, weight, 
sex, hypertension, blood pressure diastolic, blood pressure systolic, coffee, age, single 
symptoms of flank pain and macrohematuria. 
 
Metrics for estimating equation performance: 
We used Bland Altman analysis to compare measured and estimated TKV for each 
patient at baseline and assessed any bias as the median difference, where a positive value 
indicated an overestimation of TKV. The precision of the model was tested by calculating the 
interquartile range (IQR) for the difference. To assess the accuracy of the model the root 
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mean square error (RMSE) and the P30 (percentage of estimated TKV within 30% of 
measured TKV) were calculated.  
 
Metrics for triage test accuracy  
The diagnostic accuracy of the estimation equation was determined by assessing 
agreement between those selected by the triage test and those eligible for tolvaptan treatment 
based on MRI measurement of TKV.  Sensitivity and specificity were calculated for each 
estimation equation and decision threshold; the area under the curve (AUC) was also 
estimated for each TKV estimation equation [30]. For sequential triage tests an overall test 
accuracy was calculated.  
Two decision thresholds were evaluated: TKV 750 mL and TKV 675 mL. The 
threshold of 750 mL aligns with current eligibly criteria for tolvaptan treatment based on 
results from the Tempo 3:4 trial [31]. A more conservative threshold of 675 mL was also 
evaluated, which corresponds to a variability of 10% or to the growth of TKV over 2 years 
assuming a kidney-growth rate of 5%.  
In order to translate the accuracy of the triage to a meaningful metric, we used natural 
frequencies (starting with 1000 ADPKD patients) to illustrate how many patients would 
undergo further testing with MRI or not be tested based on the results of the triage test. 
We used Stata 13.1 to analyse the data.   
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Tables and Figures: 
Table 1: Baseline characteristics of the Swiss ADPKD Study  
Variable  Baseline Visit Number of patients 
Age (yr; median [IQR]) 32.91 (26.64-39.64) N=204 
Height (cm; median [IQR]) 176 (169-182) N=204 
Weight (kg; median [IQR]) 74.6 (64-86) N=204 
TKV (mL; median [IQR]) 857.62 ( 565.86-1354.83) N=204 
eGFR (mL/min/1.73 m2, median [IQR]) 82.78 (72.30 - 96.08) N=204 
Blood pressure systolic (mm/Hg; median [IQR]) 131.25 (123-142.5) N=204 
Blood pressure diastolic (mm/Hg; median [IQR]) 85 (76.75-91.75) N=204 
Blood Hamoglobin (g/dl; median [IQR]) 14.1 (13.2-15) N=199 
Blood Urea (mmol/L; median [IQR]) 5.4 (4.5-6.65) N=200 
Blood HDL (mmol/L; median [IQR]) 1.39 (1.17-1.71) N=199 
Blood Cholesterol (mmol/L; median [IQR]) 4.5 (4 - 5.2) N=200 
Blood Sodium (mmol/L median [IQR]) 141 (139-142) N=203 
Male gender (%) 56.86 (116) N=204 
Hypertension (%) 64.22 (131) N=204 
Regular coffee consumption (%) 84.8 (173) N=204 
Symptoms (%) 60.29 (123) N=204 
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Table 2: Basic Model and more extended model for estimating TKV (N=204)  
Parameter Basic model Extended model 
Coefficient P Value  Coefficient P-Value 
Intercept 6.401646    0.000 11.09414    0.000 
age  0.0039959    0.307    0.0033449     0.434 
height  0.0020876    0.675     0.001101    0.834 
egfr  -0.0119388    0.00 -0.0104033    0.000 
weight 0.0061239    0.027      0.0055365    0.056 
sex  -0.136016     0.160    -0.1628024    0.133 
hypertension  0.2434446    0.002     0.0044227    0.020 
coffee  0.1902784 0.040     0.2060419     0.008 
symptoms 0.2124064    0.002 0.2455577    0.006 
blood pressure dia 0.1888329    0.237 
sodium  -0.0321973    0.059 
cholesterol -0.1058601 0.003 
hdl  -0.0540799    0.542 
urea  0.0246082    0.202 
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Table 3: Comparison of the basic and more extended model performance for TKV  
Model 
Mean difference 
between x and y R2 Correlation  IQR RMSE  
95% Limits of 
agreement % within 30% 
Basic model 
103.894 (CI 28.342-
179.446) 0.47 0.6923 332.643-3328.183 0.45 
-990.680 -
1198.467 52.45 
 
 
Extended model 
92.553 (CI 16.903- 
168.202) 0.52 0.7199 
316.927-3357.732 
0.43 
-989.764-
1174.869 55.73 
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Table 4: Diagnostic accuracy of the first triage test and second test for the basic model and the more extended 
model  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Triage Test for TKV threshold AUC (95% CI) Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI) 
Basic model 
(N=204) 750 mL 0.83 (0.77-0.88) 
 
82.5 (74.2.88.9) 64.4 (53.7-74.3) 74.6 (66.1-81.9) 74.4 (63.2-83.6) 
Basic model 
(N=204) 
 
675 mL 88.6 (81.3-93.8) 53.1 (42.5-63.9) 70.6 (62.4-77.9) 78.7 (66.3-88.1) 
Extended model 
(N=199)  750 mL 
0.85 (0.79-0.90) 
85.5 (77.5-91.5)  64.0 (53.2-73.9) 74.6 (66.1-81.9) 78.1 (66.9-86.9) 
Extended model 
(N=199) 
 
675 mL 
 
91.8 (85.0-96.2) 55.1 (44.1-65.6) 71.6 (63.4-78.9) 84.5 (72.6-92.7) 
Second test for TKV threshold AUC (95% CI) Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI) 
Basic model 
(N=63) 750 mL 0.87 (0.77-0.96) 52.6 (28.9-75.6) 95.7 (85.2-99.5) 83.3 (51.6-97.9) 83.0 (70.2-91.9) 
Basic model 
(N=58) 675 mL 0.87 (0.77-0.97) 64.3 (35.1-87.2) 90.9 (78.3-97.5) 62.9 (38.2-90.9) 88.9 (75.9-96.3) 
Extended model 
(N=65) 750 mL 0.85 (0.76-0.95) 52.9 (27.8-77)  95.9 (85.2-99.5) 81.8 (48.2-97.7) 84.6 (71.9-93.1) 
Extended model 
(N=51)  675 mL 0.88 (0.77-0.98) 54.5 (23.4-83.3) 92.5 (79.6-98.4) 66.7 (29.6-92.5) 88.1 (74.4-96.1) 
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Figure 1: Receiver operating characteristic curve compared the discriminating ability of the basic (grey) and 
extended (black) triage tests for estimating TKV with threshold of 750 mL(dot) and TKV of 675mL (triangle) 
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Figure 2: Expected clinical decisions based on triage tools 
 
 
Caption  
Triage tests for Total Kidney Volume-based management decisions (A,B: more extended and C,D: basic model)  
and a second test after 1 to 2 years per 1000 patients for the TKV threshold of 750 mL and TKV of 675mL. 
Grey: results of the MRI examination 
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Figure 3: Expected MRI Costs per 1000 patients in a 2-year period (Assumption MRI costs 850$ per 
measurement) 
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Supplemental Figure 1: Performance of the more extended model and the basic model in 
estimating measured TKV 
 
 
 
Caption: 
A: Bland-Altman analysis of the measured TKV using MRI versus the estimated TKV 
derived from the basic model. B: Bland-Altman analysis of the measured TKV using MRI 
versus the estimated TKV derived from the more extended model.  
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Supplemental Table 1: Second test model for estimating TKV  (R2 = 43%) 
 
Parameter Basic model 
Coefficient (SE?) P Value 
Intercept 5.646692 0.000 
age -0.0047606 0.552 
egfr -0.0081697 0.049 
weight 0.0068691 0.188 
sex 0.1734301 0.239 
hypertension 0.3275095 0.016 
coffee 0.1405864 0.208 
flank pain 0.1858724 0.137 
macrohematuria 0.5008101 0.092 
bps 0.0088454 0.192 
bpd -0.0042365 0.633 
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Abstract: 
Background:  
Prediction models in autosomal dominant polycystic kidney disease (ADPKD) are useful in 
clinical settings to identify patients with greater risk of a rapid disease progression in whom a 
treatment may have more benefits than harms. Mayo Clinic investigators developed a risk 
prediction tool for ADPKD patients using a single kidney value. Our aim was to perform an 
independent geographical and temporal external validation as well as evaluate the potential 
for improving the predictive performance by including additional information on total kidney 
volume.  
Methods:  
We used data from the on-going Swiss ADPKD study from 2006 to 2016. The main analysis 
included a sample size of 214 patients with Typical ADPKD (Class 1). We evaluated the 
Mayo Clinic model performance calibration and discrimination in our external sample and 
assessed whether predictive performance could be improved through the addition of 
subsequent kidney volume measurements beyond the baseline assessment.  
Results:  
The calibration of both versions of the Mayo Clinic prediction model using continuous 
Height adjusted total kidney volume (HtTKV) and using risk subclasses was good, with R2 of 
78% and 70%, respectively. Accuracy was also good with 91.5% and 88.7 % of the predicted 
within 30% of the observed, respectively. Additional information regarding kidney volume 
did not substantially improve the model performance.   
Conclusion: 
The Mayo Clinic prediction models are generalizable to other clinical settings and provide an 
accurate tool based on available predictors to identify patients at high risk for rapid disease 
progression. 
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validation study 
 
Background: 
Prediction models in autosomal dominant polycystic kidney disease (ADPKD) are 
used in clinical settings for several purposes.  They can inform patients about their prognosis. 
They can identify patients at greatest risk of rapid disease progression who might benefit 
most from new therapies. They can also identify patients with slower disease progression 
who might benefit from a care strategy that delays treatment until a later stage [1, 2]. Finally, 
prediction models are useful for identifying patients with a particular disease risk profile who 
would be suitable for clinical trials [2, 3]. Relevant outcomes for ADPKD prediction models 
include total kidney volume (TKV) and estimated glomerular filtration rate (eGFR)[4], the 
primary clinical indicators of disease progression. Established predictors of these outcomes 
include age, sex, earlier measures of TKV and eGFR and Polycystic Kidney Disease 
genotype[5, 6].  
The vasopressin V2 receptor antagonist, tolvaptan, has been recently approved for the 
treatment of ADPKD but, due to notable side effects and expense, represents a treatment 
where good risk prediction is important for targeting use. Tolvaptan is the first approved drug 
shown to directly affect disease progression [7]; all other therapies target co-morbidities that 
may contribute to progression but do not affect the underlying disease [8]. The indication for 
tolvaptan is currently limited to patients with evidence of rapid progression in Switzerland 
and European Union according to the European Medicines Agency [9] where the expected 
benefit outweighs the risk of side effects and associated high treatment costs [10]. The 
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challenge for clinicians is to identify patients at highest risk of rapid progression without 
extensive diagnostic screening across the full patient population. Currently, TKV and the rate 
of TKV change are considered the most accurate predictors of progression [11]. However, for 
routine clinical and research purposes, direct measurement of kidney volume is less feasible 
due to time and technical demands as well as expense.  
Recently, Mayo Clinic investigators developed a risk classification system for 
ADPKD patients using a single TKV value and an accompanying prediction model [12, 13]. 
In 2016, the ERA-EDTA Working Group published a recommendation that the Mayo Clinic 
prediction model be used to discriminate patients at high risk for rapid disease progression 
[14]. However, the prognostic performance of the prediction model has yet to be evaluated in 
an external sample outside the US, which is critical for establishing accuracy and 
generalizability of risk discrimination across different patient populations [12].  
 The aim of our study was to externally validate the Mayo Clinic Model using data 
from the prospective longitudinal Swiss ADPKD study, with a patient population both 
geographically and temporally removed from the original patient population in which the 
model was developed.  We also sought to evaluate whether improved prediction performance 
could be achieved by including additional measurements of the most relevant predictor: 
height adjusted total kidney volume (HtTKV).  
 
Methods 
Swiss ADPKD Validation data 
Participants were eligible for the Swiss ADPKD study if they had an ADPKD 
diagnosis, were over 18 years of age and had an eGFR over 30 ml per min per 1.73m2 at 
enrolment [15]. For the present analysis, participants from the Swiss ADPKD study were 
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included if they were under active follow-up between 2006 to 2016, had at least one follow-
up visit and had not been treated with tolvaptan. Approximately 3% (N=6) of patients had 
Atypical ADPKD (Class 2) and were excluded from the present analysis. Visits were done at 
the university hospital in Zurich and at the Hirslanden hospital Zurich. At every scheduled 
clinical visit, data were collected on medical history, kidney imaging metrics and laboratory 
values from blood and urine samples. Clinical measurements and assays were done according 
to a protocol with standardized operating procedures [16, 17].  Following an initial visit, a 
second visit occurred within 6-12 months and then visits were scheduled annually; when a 
study participant missed a scheduled visit, a study visit occurred at the next available 
opportunity to collect MRI and other study data. The local ethics committee in Zurich 
approved the study (EK-number 1178) and all patients provided written informed consent.  
 
Mayo Clinic risk classes and eGFR prediction model  
The Mayo Clinic prediction model has been described [12].  Briefly, five risk 
subclasses with theoretical yearly percentage increases in kidney volume of <1.5% (Class 
1A), 1.5-3% (Class 1B), 3-4.5% (Class 1C), 4.5-6% (Class 1D) and >6% (Class1E) were 
defined based on age and imaging data (Figure 1) [12]. Then a linear mixed-effect model was 
used to predict eGFR after t years of follow-up using baseline (t = 0) predictors: log2HtTKV 
or risk subclass group (1A-1E) [12], sex, age, eGFR from the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) equation [18]. Years of follow-up was included as a 
linear term with a subject specific random effect. Interaction terms of years of follow-up with 
all predictors were also included in the model.  
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Outcome 
Estimated Glomerular Filtration Rate (eGFR) 
In accordance with the Mayo Clinic model, our primary outcome was eGFR at t years 
follow-up. Serum creatinine was measured at each visit by the central laboratory institute of 
clinical chemistry of the university hospital and the central laboratory in Zurich using the 
modified Jaffé method traceable to an isotope-dilution mass spectroscopy reference [17]. 
eGFR at baseline (t = 0) was estimated using the CKD-EPI equation [18].  
 
Predictors 
Total Kidney Volume (TKV) 
At every study visit, a measurement of kidney volume was taken by using a 
standardized procedure protocol for the Magnetic Resonance Imaging (MRI)[16]. MRI 
acquisitions contain a breath-hold T1-weighted fast spoiled gradient echo sequence without 
fat suppression sequence (4 mm slice thicknesses) and trans-axial T2 weighted fast spin echo 
sequences. TKV was estimated by hand contouring [16]. Height adjusted total kidney volume 
(HtTKV) was obtained by dividing TKV by patient height (ml/m).   
Statistical methods  
Baseline characteristics are given as proportions and medians (interquartile range). Patients 
were stratified into the five subclasses (1A-1E) based on the Mayo Clinic estimated kidney 
growth rates limits of 1.5%, 3.0%, 4.5% and 6% (Figure 1).   
 
            We applied the Mayo Clinic model to all participants of the Swiss ADPKD study to 
predict eGFR at t years follow-up, using log2HtTKV as a continuous predictor and keeping 
regression coefficients fixed at the values determined from the Mayo Clinic development 
 
71
sample. We also applied a second Mayo Clinic model, that replaced the baseline (t = 0) 
log2HtTKV with baseline risk subclass (1A-1E).  
 
To try to improve upon the Mayo equation predictive performance, we tested two 
modifications to the original Mayo model.  First, we included in the model a second HtTKV 
follow-up measurement (mostly within 6-12 month of the baseline measurement) to provide 
additional information on individual change in TKV (Model 1). The regression coefficient for 
the HtTKV term was refit to the Swiss ADPKD study sample, but all other regression 
coefficients were kept fixed at their original value, including the intercept. Second, we 
included information on all subsequent and available HtTKV measurements, again refitting 
the regression coefficient for the HtTKV term  while keeping all other regression coefficients 
fixed at their original Mayo Clinic values (Model 2). Updated models with and without 
interaction terms of HtTKV*years were evaluated.  
 
Evaluation of model performance  
The model fit to the validation data set was assessed using R-squared statistics and 
Akaike’s information criterion (AIC). Discrimination was visually assessed using scatter 
plots comparing observed and predicted eGFR values with an estimated regression line, line 
of equality and confidence interval. The agreement was assessed using the Bland-Altman 
analysis [19]. We followed Steyerberg’s approach to validate and update clinical prediction 
models [10].   
To compare the performance of the prediction models we estimated the continuous 
ranked probability score (CRPS) of the 3 competing models: original model, updated model 1 
and updated model 2. The CRPS is a proper scoring rule to assess univariate predictive 
distributions with smaller values indicating better predictive performance [20]. The metric 
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takes into account the entire predictive distribution of the outcome [21] and assesses both 
calibration and precision of predictive distribution. For evaluation of models with added TKV 
information, five-fold cross-validation was used given that no external validation was 
available [10].  
 
The predictor HtTKV was missing in 3% of the participant-visits. We used multiple 
imputation (MI) to impute the missing values; specifically, a Markov Chain Monte Carlo 
method was implemented and multivariate normality was assumed [22]. We generated 30 
imputed data sets for each model with HtTKV [23].  
Stata 13.1 was used for all data analysis and graphics. 
 
Results 
Characteristics of the Swiss ADPKD study sample 
Between April 2006 and March 2016, 214 patients with an ADPKD diagnosis were 
enrolled in the Swiss ADPKD study, contributing a total of 1985 person-visits. At baseline, 
the median age was 34 years (interquartile range [IQR]: 27-40), the median eGFR was 82 
ml/min per 1.73 m2 (IQR: 70-95) and the median HtTKV was 497 ml/m (IQR: 317-762). 
Swiss ADPKD study follow-up times ranged from a minimum of 0.42 years for new enrolees 
to a maximum time of 10.28 years. We assessed change from one class to another in 206 
patients from the 214 swiss ADPKD class1 patients. In total, there were 52 patients (25%) 
from the 206 Swiss ADPKD Study participants who progressed to a more severe risk class 
over the median 5 year follow-up and 7 (3%) who changed to a milder disease risk class. 
More than the half of the patients in class 1A (56%) remained in their class:  40% (10 
patients) progressed from 1A to 1B (1 patient from 1A to 1C), 18% (9 patients) progressed 
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from 1B to 1C (1 patients from 1B to 1D), 28% (16 patients) progressed from 1C to 1D (4 
patients from 1C to 1B) and 28% (15 patients) progressed from 1D to 1E (3 patients from 1D 
to 1C). 
 
Comparison of the Swiss ADPKD study sample to the Mayo development sample 
Compared to the Mayo clinic development sample of 376 patients, the average eGFR 
was higher by 11 ml/min per 1.73 m2, median age was 10 years younger, and median HtTKV 
was 155 ml/m lower in the Swiss ADPKD study patients. Swiss ADPKD patients had a 
median follow-up time of 5 years (IQR: 2 to 9 years) compared to 6 years (IQR 4-10) in the 
Mayo Clinic patients. Comparing progression rates, more patients progressed in the Swiss 
ADPKD Study at 24% across all initial risk classes compared to 11% to 16% in the Mayo 
clinic development sample, though the median follow-up was 5 years compared to 4 years in 
the Mayo Clinic.  
 
External Validation of the Mayo Clinic Model 
In the Swiss ADPKD patient group, the Mayo Clinic model with the predictor 
log2HtTKV performed well with explained variance (R2) of 78 % (Table 2), compared to the 
R2 of 69% in the development data set. Replacing baseline TKV with risk subclasses in the 
model resulted in a poorer model fit with a R2 of 70 %, which is slightly lower to the R2 of 72 
% noted in the development set.  
 
The scatter plot of observed eGFR versus predicted eGFR indicated good 
discrimination with 91.5% of the predicted within 30% of the observed when log2HtTKV 
was included as a continuous predictor (Figure 2A, table 1) and 88.7 % of the predicted 
within 30% of the observed when risk subclasses were included (Figure 2B, table 2). The 
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Bland-Altman analysis shown in Figure 3 indicated a lower bias for the log2HtTKV model 
and little distortion of the variability of the distribution, as seen from the approximate zero 
slope of the regression line.  
 
Improving the Mayo prediction model  
To evaluate whether the Mayo prediction model performance could be improved if 
additional information on TKV was available, we modified the formula to include 
subsequently TKV measurements.  Updated model 1 (number of observation= 1867), which 
included a follow-up TKV measurement, showed good overall performance with a R2 of  
77%, an AIC of 13557.91 and CRPS of 58.16 (Table 2). In updated model 2 (number of 
observation= 1344), which included all available follow-up TKV measurements, resulted in a 
slightly better CRPS of 57.24 and substantially improved AIC of 9706.15 compared to Model 
1. The R2 was reasonably similar between the updated models and similar to the original 
Mayo Clinic model. Good agreement between observed and predicted was maintained as 
shown by the high correlation (Figure 2C, 2D). Both updating models reduced the bias and 
provided a good fit to the data (Figure 3C, 3D). An interaction term of TKV*years in the 
updated models did change performance (Table 2). 
 
 
Discussion  
Accurate risk prediction is important for guiding clinical care, particularly when there 
are substantial costs to treatment. The goal of the Mayo Clinic model was to provide risk 
prediction for the ADPKD patient population; however prognostic performance has never 
been established in a broader patient sample and external validity of a prediction model is 
critical to assure accurate prediction across patient populations and therefore establish the 
model’s utility as a clinical tool.  
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Our results indicated that the Mayo Clinic model performs well in our Swiss ADPKD 
patient sample. Both models showed adequate discrimination and good calibration. The 
overall prediction performance in our sample as assessed with R2 was higher when the 
continuous predictor HtTKV was the used than when risk subclasses were used. These results 
suggest the models are generalizable and would perform well in routine clinical settings. 
Given the higher eGFRs in the Swiss ADPKD Study, these results were particularly notable, 
as poorer performance might be expected with upward shifts in the distribution of eGFR 
compared to the development set. However it should be noted that in the original Mayo 
Clinic prediction model and in our validation, an estimated eGFR from the CKD-Epi formula 
was used for the baseline assessment of kidney function. This estimation may itself introduce 
bias in the prediction of later kidney function, relative to the true GFR.  To the extent that the 
CKD-Epi formula may perform differently in the two cohorts, our results could have 
impacted. We also did not distinguish between polycystic kidney disease genotypes 1 and 2, 
and prediction performance could vary between these groups. Further the R2 is known to be 
sensitive to the range and variability of the data; thus apparent improvement in prediction 
performance based on a higher R2 in our validation cohort compared to the original 
development cohort should be interpreted with caution.  
 
It should be noted that the Mayo Clinic prediction model development set used TKV 
assessed via the ellipsoid equation [12], while the present study used the gold standard TKV 
assessment by boundary method [24], which could introduce additional variability in 
prediction performance. However, a recent study assessed patient reclassified by the Mayo 
risk classification system resulting from these different TKV assessment method. The 
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investigators found only a limited impact with a few patients reclassified mostly to lower risk 
categories [24].   
 
A second aim of our study was to evaluate whether additional information regarding 
TKV change could improve the model prediction performance. Based on the results of the 
validation study and relatively large size of the development sample, we followed 
Steyerberg’s approach [25] and fixed all regression coefficients at their original values under 
the premise that re-estimation runs the risk of replacing reliable but modestly biased 
estimators with unbiased but unreliable ones [10]. Allowing only the coefficient for TKV to 
vary, we found that the R2 remained relatively unchanged when baseline TKV was replaced 
with measurements from the first two assessments.  Further including all available TKV 
measurements, including a current TKV assessment, did not provide substantial improvement 
in the prediction performance that would justify the additional cost, time and effort of TKV 
measurement.  
 
Strengths of our study include a patient population that was entirely independent of 
the Mayo Clinic data set, varying geographically, culturally and temporally from the original 
development cohort. In addition the Swiss ADPKD study has comprehensive follow-up with 
repeated measurements of kidney volume over time in a well-described cohort of untreated 
ADPKD patients at an early disease stage. The inclusion of recently enrolled patients as well 
as those with nearly 10 years of follow-up establishes generalizability across the patient 
population. Prediction models need to perform well in general ADPKD patient populations, 
as they are used for clinical decision-making.  
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Conclusions: 
In conclusion, we found that the Mayo Clinic prediction model is an accurate tool to 
identify those at highest risk for rapid disease progression as defined by declining kidney 
function.  The performance of the model was not substantially improved with by including 
additional TKV assessments, suggesting that follow-up TKV measurements may not be 
worth the cost and burden for the purposes of predicting progression.  The Mayo prediction 
model may be a valuable tool for identifying patients for whom new treatments such as 
tolvaptan will provide benefits that outweigh the burden of side effects.  
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Tables and Figures: 
 
Table 1: Baseline characteristics of the development set from the Mayo Clinic and the 
validation set from the Swiss ADPKD Study  
     Class 
Total number # 
(%) 
Men/Women(n/n) Median Age (yr) 
Median eGFR 
(ml/min per 1.73 
m2) 
Median HtTKV 
(mL/m) 
Median Follow-
Up (yr) 
Mayo Clinic 
    1A  40 (10.6) 7/33 50(44-58) 84(64-97) 249(214-280) 5 (3-10) 
   1B  88 (23.4) 23/65 46(36-53) 78(62-97) 433(322-565) 6(3-9) 
   1C  122 (32.4) 46/76 44(36-50) 71(47-98) 701(514-1037) 6 (4-10) 
   1D  77 (20.4) 40/37 41(34-49) 60(36-96) 1195(843-1544) 6 (4-11) 
   1E  49 (13.0) 28/21 36(29-43) 46(26-94) 1874 (1118-2609) 5 (3-8) 
Subtotal  376 (100) 144/232 44(35-51) 71(44-97) 651 (431-1195) 6 (4-10) 
 
Swiss ADPKD 
   1A  27 (12.6) 9/18 29.43 (24-37) 86.67 (78-102) 199.52 (178-232) 5.19 (1.99-8.35) 
   1B  52 (24.3) 20/32 36.15 (29-46) 83.84 (72-100) 343.75 (272-421) 5.28 (3.13-7.92) 
   1C  60 (28.0) 35/25 35.56 (28-41) 83.14 (71-92) 514.31 (407-630) 4.24 (2.02-8.26) 
   1D  52 (24.3) 38/14 32.48 (28-38) 79.35 (72-94) 705.70 (579-910) 6.25 (2.85-8.95) 
   1E  23 (10.7) 18/5 29.82 (23-35) 70.30 (56-86) 1166.50 (920-1425) 6.93 (3.27-8.53) 
Subtotal  214 (100) 120/94 34.22 (27-40) 82.20 (70-95) 496.58 (317-762) 5.13 (2.21-8.48) 
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Table 2: Predictive performance of the validation, the updated models and the sensitivity 
analysis (in grey) 
  R2 Bias 95% Limits of Agreement Correlation 
% within 
30 % AIC CRPS 
Validation model: 
risk class (1985 
 observations) 
0.7039 5.29 -16.8,27.3 0.839 88.7 - - 
Validation model: 
TKV (1985 
 observations) 
0.7853 -2.73 -20.4,15.0 0.871 91.5  14386.98 73.36 
Updated model 1:  
 2 TKV’s (1867 
 observations) 
0.7704 0.42 -17.4,18.3 0.872 96.6 13557.91 58.16 
Updated model 1 
with interaction term 
0.7720 0.82 -16.9,18.6 0.879 96.6 1322.3 81.85 
Updated model 2: 
TKV time-varying 
(1344 observations) 
0.7989 0.34 -17.1,17.8 0.889 96.1 9706.15 57.24 
Updated model 2 
with interaction term 
0.8015 0.57 -16.8,17.9 0.895 96.1 9715.05 83.39 
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Figure 1: Subclassification of ADPKD patients based on HtTKV limits on their age at 
baseline. Limits are defined from the Mayo Clinic based on estimated kidney growth rates of 
<1.5% (dark green), 1.5-3.0% (mint), 3-4.5% (yellow), 4.5- 6% (orange) and >6%(red). 
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Figure 2: 2A: Scatterplot of the observed eGFR versus the predicted eGFR derived from the 
model obtained from the development set with TKV as predictor with regression line and the 
line of equality. 2B: Scatterplot observed eGFR vs. predicted eGFR derived from the model 
obtained from the development set with the five subclasses as predictor. 2C: Scatterplot of 
the observed eGFR versus the predicted eGFR derived from the updated model 1 with two 
TKV measurements and 2D: updated model 2 with time-varying TKV. 
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Figure 3: 3A: Bland-Altman analysis of the observed eGFR versus the predicted eGFR 
derived from the model obtained from the development set with TKV as predictor. 3B: 
Bland-Altman analysis observed eGFR vs. predicted eGFR derived from the model obtained 
from the development set with the five subclasses as predictor. 3C: Bland-Altman analysis of 
the observed eGFR versus the predicted eGFR derived from the updated model 1 with two 
TKV measurements and 3D: updated model 2 with time-varying TKV  
 
 
 
 
 
 
  
 
86
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
87
 
Chapter V 
 
General Discussion 
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The following discussion summarizes the main findings of this thesis and puts them 
into a broader context of ADPKD research and evidence-based management. The first paper 
of the thesis contributes to the non-pharmacological management of ADPKD patients. The 
second and third articles support evidence-based management in a clinical setting of 
expensive diagnostic tests and the selection of non-drug and drug treatments through 
prediction models. 
 
Implication for evidence-based management in clinical practice   
 
In the management of patients with ADPKD, non-medical interventions such as 
lifestyle factors are important for the control of the disease progression and hypertension. 
Avoiding high sodium/salt intake, avoiding smoking, lowering alcohol intake, reducing 
coffee intake, exercising, staying hydrated and maintaining a healthy diet are important 
lifestyle factors for ADPKD patients. Lifestyle factors are relevant for ADPKD patients to 
reduce risk factors and strengthen resources with the aim to prolong and stabilize renal 
function until renal replacement therapy (RRT) is required. Therefore, avoiding potential risk 
factors such as coffee has been recommended to delay disease progression. Our first study is 
the first prospective cohort study that assessed the association between coffee consumption 
and disease progression. The lack of an association suggests that a recommendation against 
coffee consumption may not be justified.  
 
In clinical practice, the clinical diagnosis of ADPKD in patients with positive family 
history is confirmed when the number of cyst meet the Pei-Ravine diagnostic criteria [1, 2]. 
In the later stage of clinical management when the decision for risk-stratified treatment is 
needed or patients are under treatment, the purpose of a test is to provide prognostic 
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information or monitor disease progress. Here, our triage test and the validated prediction 
model can be implemented easily (Figure 1). 
 
Figure 1: Use of a test/model in clinical ADPKD practice for diagnosis and prognosis 
(highlight the new triage test and the validation of the prediction model).   
 
 
 
Our triage test, presented in Chapter III, can be used in clinical practice to inform patients 
about their expected TKV and help clinicians to reduce the number of MRI tests that are not 
necessary in patients who will not be eligible for treatment. The high sensitivity of our triage 
test suggests that clinicians can identify such patients accurately and safe resources and cost.  
Since all variables of the triage test are readily available, clinicians can use the triage test in 
their daily practice. The implication of a clinical decision-making tool for triaging patients 
towards or away from an MRI could also form the basis of a reimbursement policy, because 
MRIs are still not reimbursed in some countries. In particular, patients in less developed 
countries could benefit from a more efficient allocation of MRI resources in clinical practice.  
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Accurate and feasible risk prognosis is essential for guiding clinical care, particularly when 
patients must be selected wisely for a drug. Our independent geographical and temporal 
external validation of the two Mayo Clinic models suggests that these models are 
generalizable in clinical settings and that they are accurate tools that use easily available 
predictors for identifying patients at high risk for rapid disease progression. Selecting patients 
for Tolvaptan treatment is justified as there are substantial side effects associated with 
treatment and so patients receiving treatment should incur benefits that ourweigh the harms.  
 
Implication for research  
The longitudinal cohort study is used in epidemiologic research to investigate 
potential associations and answer questions regarding disease prognosis, in this thesis, 
whether or not a given factor such as coffee intake in patients with ADPKD influences the 
risk of an outcome. From a broad public health perspective, cohort studies have often 
reported a beneficial effect of coffee intake on various health outcomes and coffee 
consumption could have a protective effect on avoiding for example cancer, diabetes and 
heart disease [3-5]. Besides these results, other studies also showed a negative effect of 
coffee consumption on blood values such as blood pressure and cholesterol. A dose response 
meta-analysis of 21 cohort studies showed a non-linear association between coffee intake and 
mortality from all causes and cancer. The highest risk reductions were observed by drinking 4 
cups per day; for all-cause mortality drinking coffee was not associated with higher mortality 
due to cancer [6]. In the context of the management of kidney disease, a community-based 
study showed that coffee consumption was associated with a lower risk of chronic kidney 
disease [7].  
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From an evidence-based management focus on ADPKD, the effects of caffeine have 
been insufficiently investigated to support a strong recommendation against caffeine 
consumption [8]. Our study is the first prospective cohort study that investigates the 
association between coffee consumption and disease progression in an ADPKD cohort and 
contributes a major step towards closing the reported gap in the research.  However, 
following the approach of the GRADE (Grading of Recommendations, Assessment, 
Development and Evaluations) Working Group, the current evidence base [9], which is now 
restricted to our study, would still be considered weak at best. Thus guideline developers may 
abstain from making any recommendations for or against coffee consumptions for patients 
with ADPKD and call for additional high-quality cohort studies or randomized controlled 
trials that assess the effects of coffee consumptions on disease progression.  
Our triage test for TKV-based management decisions in ADPKD is the first test 
which aims to identify patients unlikely to meet the minimal TKV thresholds required for 
tolvaptan treatment and for whom TKV measurement via MRI can be avoided. For a reliable 
implementation of our triage test, external validation is needed. Ideally, other groups would 
assess the diagnostic accuracy of our triage tests and update the underlying models as 
appropriate. Also, future studies should assess if using a triage test truly changes decision 
making on imaging tests and if patients not undergoing MRI experience negative 
consequences such as undetected rapid progression. Ideally, randomized trials would 
compare the outcomes of ADPKD patients with different management pathways such as with 
or without the triage test [10]. Alongside such studies, the cost effectiveness of these 
management pathways should be assessed. Such studies would inform guidelines on ADPKD 
management but also policies on reimbursement of MRI and treatment cost.  
There is still a need for a defined algorithm to assess indications for initiation of 
treatment in ADPKD. The clinical progression in ADPKD patients has a varying course till 
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ESRD. Several patients progress to ESRD at an early disease stage whereas others never 
reach ESRD [11]. Since patients with rapid progressive disease have the most benefit from 
aggressive treatment, prediction models that can identify them are important [12-14]. We 
validated the Mayo Clinic prediction models for the outcome eGFR and extended it by 
adding subsequent TKV measurements in our own ADPKD cohort. From an evidence-based 
management focus on ADPKD, the Mayo risk model for the outcome eGFR has been 
insufficiently evaluated regarding the initiation of treatment over a long-term perspective. For 
treatment initiation, it is necessary to consider many factors including adverse effects, 
lifestyle factors, contraindication and patient’s incentive [12].  
Figure 2: Correlation between GFR and TKV as a disease marker for ADPKD. Figure adapted and 
modified from [18]. Measured GFR (dark blue) is the  % of function depending on age. It stays very 
long stable till late decline to ESRD. % of functioning original glomeruli (light blmue) decline before 
mGFR decline. TKV (red) is increasing with age. The dashed line is the expected development under 
a treatment with tolvaptan.  
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However, eGFR as an outcome may not be the optimal measure for selecting an 
ADPKD patient, because of its characteristic as a late disease marker. Kidney function 
remains stable for a long period and serum creatinine levels only rise once the kidneys have 
serious and irreversible damage (Figure 2). Considering intake of tolvaptan for a long time 
[15, 16], GFR decline could be retarded in the future, when patients start the treatment at an 
early age [17]. Change in TKV shows disease progression at an earlier stage and with greater 
precision than change in eGFR (Figure 2). Accurate TKV estimation equations are still 
limited and a future challenge is the development of prediction models with easily available 
markers for the outcome of TKV.  
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Conclusion 
When put into the context of available evidence the three studies of this PhD thesis contribute 
to the major therapy goal of slowing down disease progression. Our results suggest that 
guideline developers may lift the recommendation to restrict coffee consumption in patients 
with ADPKD and make recommendations for or against coffee consumption only if more 
high-quality studies provide the evidence beneficial or harmful effects of coffee 
consumption. The triage tests and prediction models developed and validated here support 
patient and physician evidence-based decisions on the use of diagnostic imaging and on the 
indication of non-drug and drug therapies. Such tests are, however, only the beginning of 
developing evidence-based recommendations for testing and treatment pathways. The results 
of this thesis open the door for the judicious use of expensive imaging tests and novel 
treatments. But only a combination of additional primary studies such as randomized trials 
and of modelling studies for estimating benefits, harms and cost of testing and treatment 
pathways will ultimately inform clinical practice on the best management strategies that 
optimally balance benefits, harms and cost of patients with ADPKD. 
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Abstract 
Background: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by a 
decline in renal function at late disease stage when large portion of functional renal 
parenchyma is replaced by cystic tissue. Thus, kidney function, assessed by estimated 
glomerular filtration rate (eGFR) does not well represent disease burden at the early disease 
stage. Here we investigated various urinary markers for tubular injury and their association 
with disease burden in ADPKD patients at early disease course. 
Methods:  
ADPKD patients between 18 and 40 years with an eGFR of 70 ml per min per 1.73m2 and 
more were eligible for this cross-sectional study. Urinary Neutrophil Gelatinase-Associated 
Lipocalin (NGAL), Kidney Injury Molecule 1 (KIM-1), and Uromodulin (UMOD) were 
investigated by Enzyme-linked immunosorbent assay. Clara Cell Protein 16 (CC16) was 
investigated using Latex Immuno Assay. Cryoscopy was performed to assess urine osmolality 
and urinary albumin creatinine ratio (UACR) was calculated. Multiple regression analysis 
was applied to evaluate the association and the predictive properties of biomarkers on eGFR 
and height adjusted total kidney volume (htTKV), incorporating different control variables 
for adjustment. Applying bootstrapping method internally validated results. 
Results:  
In 139 ADPKD patients (aged 31 ±7 years) with a mean eGFR of 93 ± 19 ml per min per 
1.73 m2 the total kidney volume was negatively associated with eGFR and UMOD and 
positive associated with age, UACR, KIM-1 and urine osmolality after adjustment for 
possible confounders. Urine osmolality and htTKV were also associated with eGFR, whereas 
we found no association of CC16, NGAL and UMOD with eGFR or htTKV. 
 
 
 
101
Conclusion: 
In ADPKD urine osmolality, UACR and KIM-1 are independently associated with kidney 
size but not with renal function. Urine osmolality was associated with eGFR following 
adjustment for multiple confounders. Our results indicate that the urinary biomarkers 
osmolality, UACR and KIM-1 have the property to assess disease state at early ADPKD 
stage.  
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Introduction 
 Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common 
inherited kidney diseases. It is characterized by a decline of glomerular filtration rate at late 
disease stage and inter- and intrafamilial variability in age of end stage renal disease (ESRD) 
onset, implying a challenge to predict individuals’ disease progression. The development and 
continued accretion of cysts, as the most prominent feature in ADPKD, leads to a massive 
enlargement of the kidney and subsequently to a loss of its function. So far, no disease 
modifying treatment has been available, despite the recent approval of Tolvaptan in Japan, 
and only comorbidities, like hypertension, urinary tract infections, pain, and kidney stones 
can be treated. Due to hyperfiltration of the remaining nephrons kidney function stays stable 
over decades. Thus, traditional markers for kidney function like serum creatinine and 
estimated glomerular filtration rate (eGFR) have limited ability to accurately assess the 
disease state and to predict progression the early course of ADPKD. Increasing evidence 
suggests that total kidney volume qualifies as a marker for disease progression in ADPKD.1 
In fact, the disease state may be reflected more accurately by total kidney volume and kidney 
growth rate than renal functional parameters like eGFR or creatinine clearance.2 Total kidney 
volume can be accurately assessed by magnetic resonance imaging (MRI). However MRI 
derived kidney volume measurements are time and cost intensive and this modality is not 
routine clinical practice and requires high technical expertise.  
 Renal cystogenesis in ADPKD is a complex process, characterized by abnormalities 
in tubular cell proliferation, fluid secretion, extracellular matrix formation, and cell polarity.3 
This results in an impaired filtration barrier, diminished tubular reabsorption, upregulation of 
tubular proteins and release of markers by recruited inflammatory cells, which can be 
detected in patients’ urine.4 Biomarkers are used to define the patients’ state in a certain 
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disease condition, to predict prognosis, and to quantify the effect of a pharmacological 
approach. Mayeux et al defined two major types of biomarker. Biomarkers of disease that are 
used in the diagnosis, treatment and prognosis of a disease and biomarkers of risk exposure.5 
Type 0 biomarkers (diagnostic biomarkers) are markers reflecting the natural history 
correlating with clinical indices whereas biomarkers of type 1 (predictive biomarkers) capture 
the effect of an intervention.6 Type 0 biomarkers, reflecting tubular damage, that have been 
investigated in various settings of kidney disease and may be of interest in ADPKD are 
Neutrophil Gelatinase-Associated Lipocalin (NGAL), Kidney Injury Molecule 1 (KIM-1), 
Uromodulin (UMOD), Clara Cell Protein 16 (CC16) and albuminuria.6 NGAL has been 
extensively investigated as a biomarker, due to its rapid increase in different settings like 
acute kidney injury, cardiac surgery, and kidney transplantation.7-11 KIM-1 does not occur in 
human urine under physiological conditions and has been described as progression marker in 
kidney disease.2 UMOD, the most abundant protein in human urine, regulates tubular 
function and shows protective properties against uropathogenic E. coli and the formation of 
kidney stones. 12 Decreasing levels of urinary UMOD have been reported in various settings 
of chronic kidney disease (CKD), like glomerulonephritis, diabetic nephropathy or 
tubulointerstitial nephropathy.12-15 Urinary CC16 is consistently associated with defective 
endocytic uptake by the proximal tubule. It has been shown that CC16 levels are increased in 
patients with diabetic and HIV-induced nephropathy, as well as in renal Fanconi 
syndrome.16,17 There is an unmet need to discover new biomarkers that allow an easy and 
non-invasively assessment of ADPKD disease state. We investigated the potential properties 
of the aforementioned markers for assessing disease state by evaluating their association with 
kidney volume and renal function in patients at early stage of ADPKD.   
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Methods 
Study Subjects 
 Subjects were eligible for enrolment if they belong to the well-described SUISSE 
ADPKD cohort.18,19 Male and female patients with proven ADPKD diagnosis, examined by 
kidney ultrasonography, according to Ravine criteria, and a positive family history were 
eligible when aged between 18 and 40 and presenting with an eGFR of 70 ml per min per 
1.73m2 and above as shown in Table 1.20 In patients with negative family history, proof of a 
mutation in the PKD1 or PKD2 genes was required for enrolment (sequencing analysis by 
Athena Diagnostics Inc., Worcester, MA, USA). The study was conducted according to the 
Declaration of Helsinki and Good Clinical Practice Guidelines and was approved by the local 
ethical board “Kantonale Ethikkommission Zürich” (KEK; EK-1178). All patients provided 
written informed consent.  
Study Procedure 
 Participants were invited to the outpatient clinic at the Division of Nephrology 
(University Hospital Zurich). At the study visit the medical history was obtained, including 
medication and complications related to ADPKD. Blood pressure was measured in duplicate 
at each arm after 5 minutes of rest in sitting position using an oscillometric blood pressure 
device (Boso-Medicus, Jungingen, Germany). Hypertension was defined as systolic blood 
pressure above 140 mmHg and/or diastolic blood pressure above 90 mmHg or 
antihypertensive treatment. A fasting spot urine sample was collected after voiding the first 
urine of the day to measure creatinine beside the potential biomarkers. Blood samples were 
centrifuged and aliquoted, according to a standardized process, to obtain serum. Serum and 
spot urine aliquots were stored at –80°C before analysis.  
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Laboratory Analysis 
 At study visit, measurements of serum creatinine with the use of the modified Jaffé 
method traceable to an isotope-dilution mass spectroscopy reference were performed. 
Estimated GFR was calculated by applying the CKD-EPI equation.21 NGAL (BioPorto 
Diagnostics A/S, Hellerup, Denmark) and KIM-1 (R&D Systems Inc., Abingdon, UK) were 
analyzed using commercially available Enzyme-linked Immunosorbent Assays (ELISA) 
according to manufacturers protocol. UMOD was analyzed by a well established ELISA 
based on a sheep anti-human uromodulin antibody (K90071C; Meridian Life Science, 
Memphis, TN) as the capture antibody, a mouse monoclonal anti-human Tamm–Horsfall 
protein antibody (CL 1032A; Cedarlane Laboratories, Burlington, NC) as the primary 
antibody, and a goat anti-mouse IgG (H+L) horseradish peroxidase–conjugated protein 
(172.1011; Bio-Rad Laboratories, Inc., Hercules, CA) as a secondary antibody. Human 
uromodulin (AG 733, stock solution: 100 µg/ml; EMD Millipore, Temecula, CA) was used to 
establish the standard curve. 22 CC16 was analyzed using a Latex Immuno Assay (LIA) with 
a continuous flow method and an assayable concentration of CC16 between 0.3 and 40 
μg/L.23 Albuminuria was assessed using Synchron Systems for Microalbumin (Beckman 
Coulter Inc., Brea, California, USA). The urinary albumin to creatinine ratio (UACR) was 
calculated as follows: Albumin (mg/dl) x 1/creatinine (mg/dl) x 1000 μg/mg. The analysis of 
urine osmolality was performed by cryoscopy using a freezing point depression Advanced® 
2020-BIO Multi-Sample Osmometer (Advanced Instruments Inc., Norwood, Massachusetts, 
USA). All samples were analysed in duplicate.  
Magnetic Resonance Imaging 
 Patients underwent kidney imaging without contrast media according to a 
standardized imaging protocol. The imaging was performed using a Signa Excite HDx 
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system (GE Healthcare, Waukesha, WI, USA) and signal perception was obtained using an 
eight-channel antero-posterior-phased array surface coil. Trans-axial sequences consisted of 
two breathhold T1-weighted fast-spoiled gradient echo sequences with 3 and 4 mm slice 
thicknesses. Additionally, a trans-axial T2-weighted fast spin echo sequence with respiratory 
triggering was performed with 3 mm slice thickness. Right and left kidney volumes were 
measured and calculated using the workstation Advantage Windows workstation (4.4 GE 
Healthcare, Buc, France). Total kidney volume (TKV) was calculated by adding the left and 
right kidney volume. Measurements of renal volume were done in a blinded way by two 
trained and independent observers. The renal hilum and the vessels were excluded from renal 
volume calculation. Variability was calculated as concordance correlation coefficients (95% 
CI) and were 1.000 (0.999–1.000) for intraobserver and 0.996 (0.995 – 0.999) for 
interobserver correlations.24 
Statistical Analysis 
 The statistic program SAS 9.4 was used for data analysis. A plausibility check of the 
data preceded the statistical analysis. Univariate methods were used to characterize study 
population. Values are given in means with standard deviation. TKV and height adjusted 
kidney volume (htTKV) are reported as median, since these parameters showed a skewed 
distribution. Median is reported with interquartile range, which is the difference between the 
values of the 25th and 75th percentiles.  
 Spearman’s correlation coefficient, r or ρ (rho) was calculated to describe the 
correlation between biomarkers and eGFR and htTKV. To calculate r, reflecting the relative 
variance part, all values of the parameters are sorted and given a rank. The smallest value gets 
the rank 1 and the highest number is sorted to rank n.25 A positive r indicates a concordant 
association, whereas a negative r stands for an opposing association.  
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  The association of biomarkers with eGFR and htTKV was evaluated by incorporating 
different control variables for adjustment and following a multiple linear regression approach. 
A stratum specific correlation analysis was performed for binary and ordinal variables. 
Multiple regression analysis gives information about importance and size effect of the 
predictors on the response variable, and about the interaction between predictors. Multiple 
linear regressions specify that each predictor is linear related to the response variable through 
its regression coefficient b, otherwise a transformation of the predictor variables is required. 
Prerequisites, like the independence of predictors to each other, were evaluated and fulfilled. 
The model determination was done using scatterplots and correlation analysis to verify 
linearity between outcome variable and predictors. Subsequently the regression equation was 
formed. Predictors were selected according to logical considerations. Adjusted R2 and p-value 
were calculated as statistic measures. R2, the coefficient of determination, reflects the 
proportion response variation that is explained by the predictors.26 Predictor variables were 
added sequentially to the different models. The models were compared using the Akaike 
information criterion (AIC). The AIC is based on the likelihood and determines which model 
is more likely to be correct and comes closer to the “truth”.27 The smaller the AIC value the 
more realistic the model is, assuming, that a robust model predicts the data well containing 
preferably a low number of predictors meeting the requirement for parsimony and avoiding 
overfitting.28 Bootstrapping was applied to estimate the 2.5th and 97.5th percentile confidence 
intervals for each model. Our dataset was used as a pool from which 500 new datasets of the 
same size were randomly drawn with replacement to internally validate our model results. 
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Results 
Demographics 
 Between April 2006 and April 2011 139 ADPKD patients were consecutively 
enrolled in the study. The mean age was 31±7 years and 85 (61%) patients were male. 
Hypertension was present in 82 (78%) patients, and 80 (58%) patients were receiving 
antihypertensive medication. Among them, 50 patients were receiving angiotensin-converting 
enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), 16 were receiving 
diuretics and 14 were treated with calcium antagonists. The mean eGFR was 93±19 ml per 
min per 1.73 m2 and 74 (53%) of the patients had an eGFR greater than 90 ml per min per 
1.73 m2. The median TKV was 860 cm3 (IQR, 568 to 1191 cm3) and 52 (37%) patients had a 
TKV greater than 1000 cm3. The median htTKV was 455 cm3 (IQR, 17 to 669 cm3). The 
mean body mass index (BMI) was 24±4 kg per m2, 5 (4%) patients had a BMI lower than 
18.5 kg per m2 and 53 (38%) patients a BMI above 25 kg per m2 (Table 2). 
Analysis of biomarker  
 The results of the urinary parameters: osmolality, NGAL, KIM-1, UMOD, UACR and 
CC16 were tabulated for the complete cohort and for the eGFR and TKV strata (Table 3). 
Osmolality was measured in 139 spot urine samples and other parameters were measured in 
132 samples. The median osmolality was 364 mosmol per kg H2O (IQR, 257 to 533 mosmol 
per kg H2O). The median NGAL value was 9.8 µg per g creatinine (IQR, 5.3 to 23.7 µg per g 
creatinine) 274.6 ng per g creatinine (IQR, 131.3 to 457.3 ng per g creatinine) for Kim-1, and 
16.3 mg per g creatinine (IQR, 10.2 to 26.7 mg per g creatinine). In the whole cohort, UACR 
was 14.0 mg per g creatinine (IQR, 8.4 to 23.1 mg per g creatinine) and the median for CC16 
was 2.78 μg per l per g creatinine (IQR, 2.0 to 6.2 μg per l per g creatinine). The median of 
KIM-1 was higher among patients with a total kidney volume above 1000 cm3 than among 
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patients with a TKV lower or equal 1000 cm3. Osmolality, NGAL, UMOD, UACR and CC16 
were similar among patients with an eGFR above 90 ml per min per 1.73m2 and less or equal 
90 ml per min per 1.73m2. 
Correlation of biomarker with indices of disease progression 
 Table 4 shows the correlation of biomarker with eGFR and TKV. Estimated GFR was 
negatively correlated with TKV (r = -0.44508, p<0.05), htTKV (r = 0.45531, p<0.05), age (r 
= -0.51026, p<0.05) and UACR (r = -0.20042, p<0.05). TKV was negatively correlated with 
eGFR (r = -0.44508, p<0.05) and UMOD (r = -0.22493, p<0.05) and positively correlated 
with age (r = 0.22493, p<0.05), urinary albumin (r = 0.25524, p<0.05), osmolality (r = 
0.1949, p<0.05) and KIM-1 (r = 0.32129, p<0.05) (Table 4). Figure 1 and 2 show the 
biomarker distribution to TKV and eGFR. 
Regression analysis for htTKV and eGFR as outcome parameter 
 Simple and multiple linear regression analysis was applied to delineate the 
independent associations of urinary biomarker with eGFR and htTKV. Kidney volume is 
affected by a number of a priori known biological factors, e.g. age, gender, and glomerular 
filtration rate. Predictive variables were chosen in a step-wise approach: In model 1 (Table 5) 
eGFR (β = -0.45968, p<.0001) was selected as a predictor; the term eGFR captures race, age 
and gender. The prognostic power of eGFR to predict htTKV is 20.6% (R2 = 0.2055) with an 
AIC of -199.6. Bootstrapping revealed a percentile confidence interval of 0.0987 and 0.3374. 
 The selection of osmolality and UACR to the model 1 as independent variables 
increased the R2 to 0.3373 (percentile CI, 0.2306 – 0.4755), and the AIC to -210.7 (Table 6; 
Model 2). An increase of the UACR (b = 0.20465, p<.0001) and urine osmolality (b = 
0.32114, p<.0001) is independently of renal function, race, age, and gender associated with 
an increase in htTKV. All predictors of the model 2 are independently predictors of htTKV at 
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an alpha level of 0.1%. Estimated GFR has the most predictive power of all 3 variables in this 
model (β = -0.42435). The standardized estimate β was calculated to evaluate the predictors 
independently of their transformation and their level of measurement.  
 Adjusted R2 of model 3 was 0.3366 after selection of KIM-1, NGAL, UMOD, CC16 
to eGFR, osmolality and UACR (Table 7). A percentile confidence interval of 0.2866 to 
0.5278 was obtained in bootstrap validation. Out of these seven variables, eGFR, osmolality, 
UACR and KIM-1 are major factors in predicting htTKV. In model 3, the variable UACR is 
the second largest predictor variable with a β of 0.30403. Osmolality had a β of 0.21408, and 
KIM-1 a β of 0.18993. NGAL, UMOD and CC16 had low β-values and were minor 
determinants in the prognosis of htTKV. In model 3 osmolality, UACR and KIM-1 are 
positively correlated with kidney volume. The AIC of model 3 was -209.9. The additional 
selection of Kim-1, NGAL, UMOD and CC16 did not increase R2 and did not change AIC.  
 Subsequently different models were established to predict eGFR. In model 1 (Table 8) 
htTKV and osmolality were added on priory knowledge to predict eGFR. Both variables 
were independently associated with eGFR, and htTKV (β = -0.49803) had a larger 
association compared with osmolality (β = 0.22936). The adjusted R2 for this model is 0.2515 
(percentile CI, 0.1588 – 0.3809) and thus approximately 25% of eGFR variation is explained 
by htTKV and osmolality. 
 In model 2 (Table 9) the predictor parameters, htTKV, osmolality and UACR account 
for 22.09% of eGFR variation with an adjusted R2 of 0.2209.  A percentile confidence 
interval of 0.1319 to 0.3738 was obtained in bootstrap validation. The predictor htTKV has 
the largest impact on the outcome in this model (β = -0.48736) and osmolality showed the 
second largest value for standardized estimate (β = 0.21857). UACR has a comparably low β.  
 In model 3 (Table 10) the parameters htTKV, osmolality, UACR, NGAL, KIM-1, 
UMOD and CC16 entered the model. Height adjusted total kidney volume (β = -0.4726; 
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p<.0001) and osmolality (β = -0.27024; p = 0.006) were independently associated with 
changes of eGFR. The additional selection of NGAL, KIM-1, UMOD and CC16 resulted in a 
stable R2 and AIC. Bootstrapping revealed a percentile confidence interval of 0.1674 to 
0.4153. 
Discussion 
 The cystogenesis in ADPKD replaces functional renal parenchyma and leads to a loss of 
kidney function during patients’ lifespan. Since GFR, a traditional parameter of renal 
function, is not accurately able to assess disease state in the early disease course, the interest 
in establishing urinary biomarker for ADPKD has increased. In this cross-sectional study, we 
investigated potential biomarker at a single time point in spot urine samples of 139 ADPKD 
patients with preserved renal function. We demonstrated that urinary KIM-1, urinary 
osmolality and UACR are independently associated with kidney volume in a cohort of young 
ADPKD patients.  
 Under physiological conditions KIM-1 is only fractional expressed and an increase in 
urinary KIM-1 reflects tubular damage in the proximal S3 segment as shown in acute and 
chronic kidney injury.29 KIM-1 has been identified as novel ciliary molecule and may interact 
with the PKD2 protein Transient Receptor Potential Polycystic 2 and could be involved in 
cellular response to changes in extracellular fluid flow detected by the cilium.30 Furthermore 
expression of KIM-1 was found in murine polycystic kidneys but not in wild type mice, 
driving the hypothesis that ADPKD patients may display higher urinary KIM-1 excretion.29 
Urinary KIM-1 levels in ADPKD patients have been reported by Meijer et al showing 
increased KIM-1 levels in 24h urine samples of ADPKD compared with healthy volunteers. 
They identified an association of KIM-1 levels with total kidney volume, adjusted for age, 
gender and albuminuria. In our study, KIM-1, among the other marker of interest, showed the 
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strongest correlation with TKV. Multiple regression analysis revealed an independent 
correlation of KIM-1 with kidney volume, after adjustment for eGFR, osmolality, UACR, 
NGAL, UMOD, and CC16. In contrast KIM-1 was not associated with renal function when 
applying multiple regression analysis adjusting for renal volume, osmolality, UACR, NGAL, 
KIM-1, UMOD, and CC16.  
 Additionally to KIM-1, our study showed that urinary osmolality is reliably and 
independently associated with kidney volume and kidney function after adjusting for various 
possible confounders. ADPKD patients are known to have a defect in osmoregulation, which 
may be attributed to an alteration in ADH release from the pituitary glands.31 An impaired 
urine concentration capacity can be observed even in children.32 With our study we confirm 
and extend the knowledge about the independent association of osmolality and TKV as 
shown by Ho et al.31 Hence, the assessment of osmolality in clinical practice, will add further 
information for disease state assessment in ADPKD patients at early disease stage.  
 Furthermore our results show that urinary albumin creatinine ratio independently predicts 
htTKV in ADPKD after multiple adjusting. Albuminuria has long been known as marker for 
kidney damage and is routinely assessed in the diagnosis of renal injury. UACR is 
independently associated with renal and cardiovascular disease. In our study urinary albumin 
excretion predicts the variation in htTKV but did not qualify as predictor for kidney function, 
expressed as eGFR. Our results confirm and extend former studies reporting a positive 
correlation of albumin excretion and total kidney volume.24 
 KIM-1, urine osmolality and albuminuria are independently associated with ADPKD 
disease state whereas we were not able to associate NGAL, UMOD and CC16 with kidney 
volume and function at early ADPKD state. Although these markers have been extensively 
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studied as biomarker in acute kidney injury, only limited data is available reporting NGAL 
levels in ADPKD.7-11 Boligano et al reported markedly increased urinary NGAL levels in 
ADPKD patients at late disease state (eGFR 59 ± 38 ml per minute, Cockcroft-Gault 
formula) compared with healthy volunteers.33 It seems that NGAL levels increase only at late 
disease state and thus NGAL is not suitable to predict outcome at early stage when renal 
function is maintained. UMOD and CC16 levels have so far not been reported in ADPKD. In 
our study, no association of UMOD with renal function and kidney volume was observed. 
Decreasing levels of urinary UMOD, which is the most abundant protein in human urine, 
have been reported in various settings of CKD.12-15 Since the absolute values for urinary 
UMOD in our cohort are comparable with the ones reported in various cohorts, one could 
speculate that UMOD excretion decline starts in later stage of ADPKD and UMOD would 
qualifying as marker for late disease course.34 35 
 Furthermore, no association of CC16 with renal function and kidney volume was 
observed, suggesting that proximal tubular reabsorption is not impaired among ADPKD 
patients at early disease state. CC16 is secreted by bronchial Clara cells and, after filtration, 
reabsorbed by receptor-mediated endocytosis in the early segments of the proximal tubule.17 
Hence, all disorders associated with defective proximal tubule endocytosis lead to the urinary 
loss of CC16. 36 The dissociation of CC16 from Kim-1 probably reflects the functional 
segmentation of the proximal tubule, with endocytosis being particularly active in the S1-S2 
segments whereas secretory pathways take place in the S3 segment.37  
 Our study has to be interpreted in the context of the study setting. We investigated 
potential biomarker and outcome in ADPKD following a cross-sectional approach. 
Biomarkers should be easily assessable from samples in a facile non-invasive way. The 
utilization of spot urine samples is ideal for this application. We enrolled a relatively high 
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number of participants at early disease course presenting preserved renal function. We report 
independent association between biomarker and outcome, but are not able to draw 
conclusions in respect to causal relationship. We cannot state if renal function and kidney 
volume follows the increase or decrease in biomarkers or if the urinary biomarker excretion 
causes change in renal function and kidney volume. Our results are based on a single centre 
in the absence of comparative groups of healthy volunteers and of patients with chronic 
kidney disease others than ADPKD and thus we cannot assess the specificity of our findings 
for ADPKD. Internal validation was performed by bootstrapping method to account for the 
limitation of studying the biomarkers in a single cohort without external validation data set. 
Our predictive models were established applying adjustment for multiple confounders. Still, 
multiple adjustments are not able to fully eliminate the potential for bias and confounding is 
likely to persist. 
 In conclusion, our results show that osmolality is an independent predictor for kidney 
volume and kidney function after adjusting for various possible confounders. The assessment 
of osmolality in clinics, will add additional information for disease state assessment and will 
precise the prognosis in ADPKD patients. Furthermore, our data shows that UACR and KIM-
1 predict kidney volume independently of renal function. In our study, we followed a robust 
and reliable statistical approach to investigate the diagnostic properties of different urinary 
biomarker in a large cohort of ADPKD patients in early disease stage. Osmolality, UACR 
and KIM-1 have the property to assess disease state at early ADPKD disease course.  
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Figures  
Figure 1: Estimated glomerular filtration rate (eGFR) and parameter distribution 
0
5
10
15
20
25
40 90 140
ht
TK
V 
(c
m
3 
pe
r m
)
eGFR (ml per min per 1.73m2)
r=-0.45531
p<0.0001
0
10
20
30
40
50
40 90 140
ag
e 
(y
ea
rs
)
eGFR (ml per min per 1.73m2)
r=-0.51026
p<0.0001
0
50
100
150
40 90 140N
GA
L (
µg
 p
er
 g
cr
ea
tin
in
e)
eGFR (ml per min per 1.73m2)
r=-0.06826
p=0.4368
0
200
400
600
800
1000
1200
40 90 140
O
sm
ol
al
ity
  
(m
os
m
ol
 p
er
 k
g 
H 2
O
)
eGFR (ml per min per 1.73m2)
r=0.13563
p=0.1114
 
119
 
 
Abbreviations: htTKV –height adjusted kidney volume, NGAL – Neutrophil Gelatinase Associated 
Lipocalin, KIM-1 – Kidney Injury Molecule 1, UMOD –Uromodulin, UACR – Urinary Albumin-
Creatinine-Ratio, CC16 – Clara Cell Protein 16 
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Figure 2: Total kidney volume (TKV) and parameter distribution 
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Abbreviations: eGFR – estimated glomerular filtration rate, htTKV –height adjusted kidney volume, 
NGAL – Neutrophil Gelatinase Associated Lipocalin, KIM-1 – Kidney Injury Molecule 1, UMOD –
Uromodulin, UACR – Urinary Albumin-Creatinine-Ratio, CC16 – Clara Cell Protein 16 
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Appendix II: 
 
Chancen und Herausforderungen von Tolvaptan zur Behandlung von ADPKD – Ein 
aktueller Stand der Entwicklung 
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Einführung 
Tolvaptan (Samsca®) fördert die renale Ausscheidung von freiem Wasser und wird 
deshalb als Aquaretikum bezeichnet. Die chemische Strukur von Tolvaptan besteht aus einem 
C26H25ClN2O3 Molekül und ordnet sich in die neue Arzneimittelklasse genannt Vaptan und 
Aquaretika ein. Das first-in-class Medikament blockiert selektiv den Vasopressin-2 (V2) 
Rezeptor im distalen Sammelrohr und hebt somit die physiologische Wirkung von 
Vasopressin (Synonym Antidiuretisches Hormon (ADH)) auf. Die Aktivierung des V2-
Rezeptors durch Vasopressin führt über cyclischem Adenosinmonophosphat (cAMP) zur 
vermehrten Translation von Aquaporinen, welche die Tubuluszellen wasserdurchlässig 
machen. Tolvaptan verhindert diesen Prozess und somit bleiben die Tubuluszellen für Wasser 
undurchlässig und die Rückresorption von Wasser aus dem Primärharn in das Blut wird 
verhindert. Es kommt entsprechend zu einer starken Polyurie, insbesondere bei normaler 
Nierenfunktion. Im Gegensatz zu einem konventionellen Diuretika, verursacht Tolvaptan 
keinen Elekrolytverlust. Tolvaptan ist zur Behandlung von kardial bedingten Ödemen und 
des Syndroms der inadäquaten ADH Sekretion (SIADH) von der European Medicines 
Agency (EMA) und der Food and Drug Administration (FDA) zugelassen [1]. Ein 
Zulassungsantrag an die Swissmedic für diese beiden Indikationen wurde bisher nicht 
gestellt. 
Die autosomal-dominante polyzystische Nierenerkrankung (Englisch autosomal 
dominant polycystic kidney disease) ist eine monogene vererbbare Erkrankung, welche durch 
die Entwicklung von einer Vielzahl von Zysten in beiden Nieren gekennzeichnet ist. Häufig 
werden betroffene Patienten zwischen dem 50. und 60. Lebensjahr nierenersatzpflichtig. 
ADPKD Patienten zeigen bereits in frühen Stadien eine eingeschränkte 
Urinkonzentrationsfähigkeit der Niere mit begleitend erhöhten Vasopressinspiegeln [1]. 
Vasopressin erhöht die Konzentration von cAMP, welches pro-proliferative Signalwege und 
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die chloridabhängige Flüssigkeitssekretion in die Zysten stimuliert. Der verstärkten 
Aktivierung des V2-Rezeptors bei ADPKD wird somit eine kausale Rolle in der 
Krankheitsprogression zugeschrieben.  
 
Studienresultate  
Die Therapieeffizienz von Tolvaptan zur Behandlung von ADPKD wurde in einer 
multizentrischen doppelblinden Placebo kontrollierten Phase III-Studie (TEMPO 3:4) 
geprüft, in welcher 1445 ADPKD Patienten im Alter von 18 bis 50 Jahren eingeschlossen 
wurden. Der primäre Endpunkt war das prozentuale Nierenwachstum und als kombinierter 
sekundärer Endpunkt: die Verschlechterung der geschätzten glomerulären Filtrationsrate, der 
Albuminurie, der Hypertonie, sowie der Inzidenz von behandlungsbedürftigen 
Nierenschmerzen. Über einen Beobachtungszeitraum von 3 Jahren zeigten die Ergebnisse der 
Studie eine Zunahme des Nierenvolumens von 2,8% pro Jahr in der Tolvaptangruppe 
verglichen zu der Placebogruppe von 5,5% pro Jahr. Tolvaptan senkte somit die 
Wachstumsrate des Nierenvolumens um 2,7 % pro Jahr (95%CI von -3.3 bis -2.1). Zudem 
wurde der Nierenfunktionsverlust in der Tolvaptangruppe, im Vergleich zur  Placebogruppe, 
vermindert. Weiterhin konnte in der Tolvaptangruppe ein schützender Effekt der ADPKD-
assoziierten Komplikationen, wie Nierenschmerzen, Infektion der Harnwege und Blut im 
Urin (Hazard ratio: 0.87; 95% CI, 0.78 - 0.97) aufgezeigt werden [2].     
Als unerwünschte Nebenwirkungen, die auf den Wirkmechanismus von Tolvaptan 
zurückzuführen sind, wurde eine Polyurie in der Tolvaptan Gruppe von 38,3% versus 17,2% 
in der Placebo Gruppe beobachtet. Als weitere gehäufte unerwünschte Nebenwirkungen in 
der Tolvaptan Gruppe wurde Pollakisurie (23,2 % versus 5,4%), Nykturie (29,1% versus 
13,0%) und Durst (55,3% versus 20,5%) berichtet. Überaschenderweise zeigte sich in der 
Tolvaptangruppe eine Häufung von Leberenzymerhöhungen (0,9% und 0,4% Inzidenz in der 
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Tolvaptan- und der Placebo-Gruppe), wovon 4,7% klinisch bedeutsam waren und 
vorwiegend in den ersten 18 Studienmonaten auftraten. In der Studie wurden drei Hy’s Law 
(zwei während des Behandlungzeitraum) identifiziert, jedoch ist es bei diesen Fällen zu 
keinem lebensbedrohlichem Ereignis gekommen (Leberversagen, Transplantation oder Tod). 
Für die Identifikation eines Hy’s Law Case in einer klinischen Studie müssen die drei 
nachfolgenden Kriterien zutreffen: ein erhöhter Aminotransferasewert von >3xULN, eine 
akalische Phosphatase (ALP < 2x ULN), sowie ein erhöhter Gesamtbilirubinwert von > 2x 
ULN.    
Die Feststellung von zwei oder mehr Hy‘s Law in einer klinischen Studie ist ein starker 
Indikator für eine mögliche medikamenten-induzierte Leberschädigung (Englisch drug-
induced liver injury, DILI).  
   In der vorliegenden Studie scheint ein Anstieg der Alanin-Aminotransferase (ALT) 
öfters bei der Behandlung mit Tolvaptan vorzukommen. Diese Tolvaptan-assoziierte 
Leberenzymerhöhung wurde in vorgehenden klinischen Studien nicht beobachtet. In 
Nachfolgestudien und klinischer Anwendung ist daher ein enges Monitoring der Leberwerte 
erforderlich.   
 
Stellenwert einer Tolvaptan Therapie auf die Kosten-Effektivität 
Die Kosten-Effektivität einer  Tolvaptantherapie bis zur Notwendigkeit eines 
Nierenersatzverfahrens wurde in einem gesundheitsökonomischen Markov-Model analysiert. 
Das Ziel der Studie war die Berechnung eines qualitäts-adjustierten Lebensjahr (QALY) der 
Tolvaptan Therapie auf unterschiedliche ADPKD Populationen. Die Ergebnisse zeigen, dass 
eine Therapie (bei Patienten ab 40 Jahren und einer geschätzten glomerulären Filtrationsrate 
von 80 ml/min/1,73 m²) im Vergleich zur keiner Therapie, die mediane Zeit bis zur 
Notwendigkeit eines Nierenersatzverfahrens auf 6,5 Jahre herauszögert und die 
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Lebenserwartung sich durchschnittlich um 2,6 Jahre erhöht. Ausgehend von dem aktuellen 
Handelspreis (montl. pro Patient 5.760 $) müssten um ein QALY durch die Tolvaptan 
Therapie zu gewinnen, nahezu 750.000 $ pro Jahr investiert werden. Die Studie zeigt auf, 
dass eine Zulassung von Tolvaptan für die Therapie von ADPKD zum derzeitigen 
Handelspreis mit sehr hohen Kosten verbunden wäre [3]. Allerdings ist zu erwarten, dass bei 
einer Zulassung von Tolvaptan zur Behandlung von ADPKD das Preisniveau angepasst wird, 
da es sich um eine lebenslange Therapie handelt. Die momentane Preisgestaltung wurde für 
die Indikation bei einer Kurzeittherapie des Syndroms der inadäquaten ADH-Sekretion 
(SIADH) festgelegt.  
 
Aktuelle Entwicklung & Ausblick 
Auf Grund von umfassenden Analysen von Krankenversicherungsdaten wurde 
ADPKD durch die FDA der Status „Orphan Disease“ vergeben. Die FDA hat sich im August 
2013 gegen die Zulassung von Tolvaptan für ADPKD ausgesprochen und weitere Daten und 
Analysen vom Otsuka, dem Produzenten von Tolvaptan, sowie ein günstigeres Nutzen-
Risiko-Verhältnis gefordert [4]. Ende Dezember 2013 wurde der Zulassungsantrag für 
Tolvaptan in der Indikation ADPKD an die EMA übermittelt. Der EMA Entscheid wird in 
einem Jahr erwartet. In Japan wird derzeit ebenfalls die Zulassung für Tolvaptan als Therapie 
für ADPKD geprüft und für das zweite Quartal 2014 ist die Freigabe geplant [5]. Otsuka 
Schweiz hat das Zulassungsdossier für Tolvaptan in der Indikation ADKPD im ersten Quartal 
2014 bei Swissmedic eingereicht, somit ist eine mögliche Markzulassung von Tolvaptan in 
der Schweiz frühestens im Jahr 2015 zu erwarten. Die von der FDA geforderte 
Nachfolgestudie ist in der Planungsphase (Outcome: Nierenfunktion) und der Einschluss der 
ADPKD Patienten soll ab Juni/Juli 2014 erfolgen. Die Studiendauer beträgt ein Jahr und 
circa 1000 ADPKD sollen weltweit eingeschlossen werden.  
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